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BACKGROUND FOR 
THE STUDIES
THE DIAGNOSES INCLUDED
RHEUMATOID ARTHRITIS
Rheumatoid arthritis has an annual incidence of approximately 0.2 per 1000 in males 
and 0.4 per 1000 in females. A prevalence of 0.5–1% is reported in diverse 
populations worldwide, although a greater prevalence has been reported in certain 
Native Americans and the disease is reported to be absent in parts of rural Africa (1).
The currently accepted classification scheme for rheumatoid arthritis (RA) is the 
1987 American Rheumatism Association (ARA) criteria as presented in Table 1 (2).
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Table 1.  The 1987 American Rheumatism Association (ARA) criteria for 
rheumatoid arthritis (RA)
1 Morning stiffness Morning stiffness in and around the joints, 
lasting at least one hour before maximal 
improvement
2 Arthritis in three or more joint areas* Soft tissue swelling or fluid (not bony 
overgrowth) observed by a physician, present 
simultaneously for at least six weeks
3 Arthritis of hand joints Swelling of wrist, MCP or PIP joints for at least 
six weeks
4 Symmetric arthritis Simultaneous involvement of the same joint 
areas (defined in two) on both sides of the body 
(bilateral involvement of PIP, MCP or MTP joints 
is acceptable without absolute symmetry) for at 
least six weeks
5 Rheumatoid nodules Subcutaneous nodules over bony prominences, 
extensor surfaces or in juxta-articular regions, 
observed by a physician
6 Rheumatoid factor Detected by a method positive in fewer than 5% 
of normal controls
7 Radiographic changes Typical of RA on posteroanterior hand and wrist 
radiographs; it must include erosions or 
unequivocal bony decalcification localized in or 
most marked adjacent to the involved joints (OA 
changes alone do not qualify)
At least four criteria must be fulfilled for classification of RA; patients with two clinical 
diagnoses are not excluded. *Possible areas: right or left PIP, MCP, wrist, elbow, knee, 
ankle, MTP
In the past decade, treatment strategies for patients with rheumatoid arthritis (RA) 
have changed dramatically. Patients are being treated earlier and more aggressively 
than in the past and a much greater number of therapeutic options are available, 
which has increased the complexity of the management of patients with rheumatoid 
arthritis (3).
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ANKYLOSING SPONDYLITIS
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that affects the 
axial skeleton, causing characteristic inflammatory back pain, stiffness, and often 
peripheral arthritis. Prevalence figures for ankylosing spondylitis that can be 
extrapolated from population studies and HLA-B27 frequency yield figures ranging 
from 0.1% in the Netherlands to 1.1-1.4% in North Norway. Clinical features, age at 
onset, survival time and incidence have remained stable over time (4-7). Most, but 
not all, studies have reported a male/female predominance, with ratios in the order of 
2-3:1. (6;8)
Different criteria sets for AS have developed over time. The New York 
classification criteria, modified in 1984, are widely accepted, Table 2 (9).
Table 2. The 1984 Modified New York Criteria
1 Low back pain for at least three months' duration improved by exercise and not 
relieved by rest
2 Limitation of lumbar spine motion in sagittal and frontal planes
3 Chest expansion decreased relative to normal values for age and sex
4a Unilateral sacroiliitis grade 3-4
4b Bilateral sacroiliitis grade 2-4
Definite ankylosing spondylitis if: (4a OR 4b) AND any clinical criterion (1-3)
Actually, the modified New York criteria are classification criteria with typically 
high specificity (98%). The sensitivity (83%) is acceptable, and the modified criteria 
are proposed to serve as diagnostic criteria as well. However, these criteria are not 
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appropriate for an early diagnosis since ‘limitation of the lumbar spine’ and 
‘limitation of chest expansion’ reflect disease duration, and these features are usually 
not present in early disease (10).
POSTPOLIO SYNDROME
Approximately 10 000 persons with sequelae after acute poliomyelitis are currently
living in Norway. The majority of these persons are probably suffering from the 
“second polio illness,” i.e. postpolio syndrome (PPS) (11). This condition afflicts 
persons with polio sequelae 20 - 40 years after the acute stage of the disease (12).
The term post-polio syndrome was introduced by Halstead in 1985 to cover medical, 
orthopaedic and psychological problems possibly or indirectly related to the long-
term disability occurring many years after the acute viral polio infection. Halstead’s
criteria for PPS were as follows:
1. Confirmed history of polio.
2. Partial or fairly complete neurological and functional
recovery after the acute episode.
3. Period of at least 15 years with neurological and functional stability.
4. Two or more of the following health problems
occurring after the stable period: extensive fatigue,
muscle and/or joint pain, new weakness in muscles
previously affected or unaffected, new muscle atrophy,
functional loss, cold intolerance.
5. No other medical explanation found (13).
Halstead revised these criteria in 1991 and added  -gradual or abrupt onset of new 
neurogenic weakness- as a necessary criterion for PPS, with or without other co-
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existing symptoms (14). An electromyography (EMG) may be used to verify the 
sequelas after a polio infection with typical lower motor neuron involvement:
neurogenic EMG findings, normal sensory findings and normal motor findings 
except for parametres reflecting muscle atrophy (15).
HEREDITARY, CONGENITAL NEUROMUSCULAR 
DISEASES 
The umbrella term ‘neuromuscular diseases’ incorporates a range of conditions that 
vary appreciably depending on the site and progression of the disease (16). The
number of persons suffering from a neuromuscular disease in Norway is 
approximately 5000 (17-22). The heterogeneous group of neuromuscular diagnoses 
can be divided into three main groups: myopathies where the disease is located in 
the muscle fibre or its energy metabolism, disease in the peripheral nerves 
(neuropathies) and neuromyopathies where both the muscle fibers and the nerves are 
affected (17-22). The patients included in our study suffered from hereditary, 
congenital neuromuscular diseases of all of these three main groups, the most 
frequent diagnoses included are presented in Table 3. These diseases were 
considered relatively slowly progressive (18;19;22).
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Table 3  Diagnoses of the Hereditary, Congenital 
Neuromuscular Diseases included in the study
Hereditary motor and sensory neuropathy, HMSN (n) 23
Limb-girdle muscular dystrophy (n) 10
Myotonic dystrophy (n) 11
Spinal muscular atrophy (n) 3
Others (n)
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Charcot-Marie-Tooth disease (CMT) is the most frequent form of the Hereditary 
Motor and Sensory Neuropathies (HMSN). Distal palsy, atrophy and loss of 
sensibility are clinical signs characterising these patients, the underextremities are 
typically affected first (20;21). The hereditary myopathies typically affect proximal, 
axial and sometimes facial musculature, and the affection is often symmetrical.
Muscular fatigue and reduced tolerance for physical activity are typical signs of a 
myopathy (23). Dystrophia Myotonica (DM) is the most frequent diagnosis among 
the hereditary myopathies, characterised clinically by a combination of muscular 
weakness caused by the dystrophia, and myotonia as a consequence of changed 
stability over the muscular cell membrane (17).
Even though neuromuscular disorders are a heterogenic group both in terms 
of pathophysiology and clinical manifestations, it is still possible to identify common 
impairments that influence quality of life and the ability to cope with everyday 
living. Some of the common problems and complaints are muscle weakness of 
various severity, exercise intolerance, reduced endurance, fatigue, pain and problems 
with ambulation (17;24;25).
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EFFICACY OF PHYSICAL 
ACTIVITY, EXERCISE AND AN IN-
PATIENT REHABILITATION 
PROGRAMME 
Physical activity is “any bodily movement produced by contraction of skeletal 
muscle that results in increased energy expenditure.” Physical activities, which 
include sports and recreational activities, occupational activities, and daily-living
activities, are important for maintaining general health and for modifying the risk of 
chronic diseases. Exercise, a sub-set of physical activity, is specially designed to 
maintain or improve physical fitness. It consists of planned, structured and repetitive
movement of parts of or the whole body (26).
Comprehensive rehabilitation may be defined as systematic multidisciplinary
treatment given by physicians and health professionals. The rehabilitation 
programmes should include physical therapy with exercise aiming at improved 
aerobic fitness, muscle strength, mobility and balance, occupational therapy, and 
self-management programmes. A rehabilitation programme must include individual 
assessments and treatment plans targeting defined treatment goals.
RHEUMATOID ARTHRITIS
People of all ages with RA tend to exhibit cardiovascular deconditioning, muscle 
weakness, stiffness, poor endurance and decreased lean body mass (27). Rest 
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therapy, the antithesis of exercise, was earlier prescribed because of the fear that 
vigorous motion of arthritic joints could damage delicate periarticular tissues. Rest or 
immobilization was thought to have a specific salutary effect on inflamed joints. 
Ytterberg et al. reviewed the data available concerning exercise for arthritis in 1994, 
and concluded that range of motion (ROM), strengthening and aerobic conditioning 
exercises were safe for patients with osteoarthritis (OA), RA or AS (28).
The objectives of exercise therapy in patients with RA are restoration, 
preservation or increase of joint range of motion, muscle strength or cardiovascular 
condition (28). Several studies have demonstrated that different exercise 
interventions are profitable for RA patients (27;29;30).
Whether the effects of physical training persist in a long-term perspective was 
studied by Hansen et al.  in 1993. The participants of his study followed different 
exercise programmes over the course of two years and were evaluated by objective 
parametres like ESR, SJC and X-ray, concluding that although most patients 
appreciated training, the present study could not support that training lessons affect 
the disease activity or the progression of the disease (31). Stenström et al. ascertained 
the effects of once-weekly, intensive dynamic training in water of patients with RA 
after a four-year training period, demonstrating significantly better grip strength and 
higher activity level in the intervention group compared to a control group, and 
significantly more admittances for acute hospital care in the latter. The conclusion 
supports Hansen et al. that dynamic training does not seem, even from a long 
perspective, to lead to any undesirable consequences (32).
In 1998, van den Ende et al. reviewed the available studies on dynamic 
exercise therapy of durations of eight weeks to two years in rheumatoid arthritis (33).
On the basis of the six included studies, they concluded that dynamic exercise 
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therapy is effective in increasing aerobic capacity and muscle strength, and that no 
detrimental effects on disease activity and pain were observed (31;34;35). Still, 
further research on the long-term effect of dynamic exercise therapy on radiological 
progression and functional ability is needed.  
In 1994, Stenström found no correlation between radiologically observed 
progression of joint destruction and self-selected exercise frequency in patients with 
rheumatoid arthritis during a four year study period (36). A two year high-intensity 
exercise programme showed to be more effective than usual care in improving the 
functional ability of RA patients in the randomized, controlled, multicentre trial of de 
Jong et al. in 2003. The intensive exercise did not increase the radiographic damage 
of the large joints, except possibly in patients with considerable baseline damage of 
the large joints (37).
In 2003, Stenström and Minor reviewed the evidence for the benefit of 
aerobic and strengthening exercise in RA, supporting van den Endes’ conclusion 
about efficacy and lack of detrimental effects, now including “no radiological joint 
damage” as well (38). As early as 1981, Nordemar et al. had presented a follow-up
study of physical training in RA patients for a  four to eight year period, revealing a 
significantly less pronounced progress of X-ray changes in the joints of the active 
patients compared with comparable control patients (39).
Regular dynamic strength training combined with endurance-type physical 
activities improves muscle strength and physical function, but not Bone Mineral 
Density (BMD), in patients with early RA, without detrimental effects on disease 
activity. This was the conclusion of the randomized two-year study of the effects of
dynamic strength training of Häkkinen et al. in 2001 (40). In a follow-up study, they 
demonstrated that the muscle strength gains were maintained throughout a 
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subsequent self-monitored training period of three years. Despite substantial training
effects in muscle strength, BMD values remained relatively constant. Radiographic 
damage remained low even at five years (41). On the other hand, a long-term high-
intensity weight-bearing exercise program for RA patients has been shown to be 
effective in slowing down the loss of BMD at the hip (42).
In conclusion, there is high evidence for the immediate efficacy of different 
exercise modalities in RA patients, as well as the lack of detrimental effects on 
disease activity, radiologic progression and BMD values even in the long-term 
aspect. Some studies have even suggested exercise therapy to be effective in slowing
down the progress of X-ray changes in the joints and the loss of BMD in the hip 
(39;42). The results of some long-term studies of the benefits of aerobic and 
strengthening exercises are more conflicting. This might be explained by the 
differences in the outcome measures chosen. It seems to be harder to demonstrate 
improvements in disease activity measures than in measures of aerobic capacity, 
muscle strength, physical function and symptoms. 
Little is known about the optimal model(s) for providing rehabilitative care 
for patients with RA and AS. Rehabilitative care may be provided by single health
professionals or by a multidisciplinary team coordinating their activities. There is 
some evidence that a comprehensive package of care, delivered in the community 
and addressing patient specific needs through education, exercise and pain relief 
modalities has long-term benefits for self-efficacy, disease management knowledge 
and some measures of disease activity and function (43;44).
Studies of intensive in-patient multidisciplinary treatment of arthritis patients 
have shown to be more effective than regular physical exercise and physiotherapy
alone (Table 4)   (45-48). In spite of this, reviews in this field are cautious in their 
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conclusions. Vliet Vlieland concluded in her review from 1997 that favorable effects 
on disease activity were seen in most trials comparing short inpatient team care with 
regular outpatient care. However, proof of efficacy of prolonged outpatient team care 
is scanty and results of trials comparing inpatient with outpatient team care remain 
inconclusive (49). Rehabilitation of people with rheumatoid arthritis was the subject 
of a Best Practice and research publication of the same author in 2003 (50),
concluding that despite widespread positive clinical experience with rehabilitative 
interventions, the scientific evidence of their effectiveness is, in general, scanty, 
owing to a lack of studies with sufficient methodological quality.
In Hammond’s critical review of rehabilitation in rheumatoid arthritis from 
2004 (51), the author concludes thoughts on evidence to date in this way. Over at 
least a one-year period, the following are effective in reducing pain and maintaining 
function: patient education and joint protection training using behavioural 
approaches; dynamic exercise therapy, hand exercises and hydrotherapy; and 
cognitive-behavioural therapy. Symptomatic relief results from thermotherapy, laser 
therapy, acupuncture and assistive devices. In the short-term, comprehensive 
occupational therapy, orthoses, and mind-body approaches can help maintain 
function. Many trials have recruited people with moderate to severe, established RA 
and relatively little is known about the long-term effectiveness of early rehabilitation, 
although this is becoming much more common in practice. Despite the increased 
availability of guidelines and systematic reviews, most conclude there is insufficient 
evidence for many areas of rheumatology rehabilitation. Further well-designed 
clinical trials recruiting people with early disease using patient-centred outcomes are 
needed.
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Uhlig et al. have reviewed the effectiveness of comprehensive rehabilitation 
programmes, concluding that when effects on the various outcome measures are 
demonstrated, improvements can only with difficulty be attributed to a specific 
component of a comprehensive program (52). Economic analyses for the 
effectiveness of comprehensive programs are scarce, but are needed by policy 
makers to allow the optimal allocation of resources. Preferably the overall 
performance of comprehensive rehabilitation programs, not the individual 
components, should be evaluated (52).
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Table 4.  Studies of comprehensive in-patient multidisciplinary treatment of 
Rheumatoid Arthritis patients
First author, 
year of 
publication 
Number of patients
(n), design,
Results
Vliet Vlieland
1996 (46)
N=80,
RCT of 11 days in-
patient multidisciplinary 
treatment versus 
routine out-patient care
Improvements in favour of the in-patient group: 
 Disease activity
 % with an ACR response
 Emotional status 
The improvement in laboratory and functional 
measures did not differ between the groups
Vliet Vlieland 
1997
(47)
N=80,
A two-year follow-up of 
the RCT of Vliet 
Vlieland in 1996 (46)
 Improvements in favour of the in-patient 
group in all endpoint measures, except 
for the ESR and HAQ score
 The beneficial effect on disease activity 
persisted over a period of one year
van den 
Ende 2000 
(45)
N= 64,
RCT of an intensive 
versus a conservative 
exercise programme 
during an in-patient 
hospital stay with a 
mean length of 30 days
 	
	
			
conservative exercise group, respectively 
(week 24)
 Physical functioning improved for 
patients in the intensive exercise group
 Muscle strength differed between the 
groups
Y. Bulthuis 
2007 (48)
“The 
DAPPER 
study”
N=98, 
RCT of an intensive in-
patient exercise training 
(IET) for three weeks 
immediately after 
discharge from hospital 
compared to usual care 
(UC) 
The IET showed a better and faster 
improvement than UC on all outcome measures 
for:
 Range of motion 
 Disability 
but not for the HRQoL measures. The DAPPER 
programme results in regaining of function which 
lasts up to 52 weeks
RCT; randomised, clinical trial, ACR; American College of Rheumatology, ESR;
erythrocyte sedimentation rate, HAQ; health assessment questionnaire, DAS; Disease 
Activity Score, HRQoL; health-related quality of life 
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ANKYLOSING SPONDYLITIS
Physiotherapy and supervised exercises are widely accepted as part of the non-
pharmacologic treatment of patients with AS (53). The physiotherapy intervention 
aims to prevent and/or retard restriction of spinal mobility and the development of 
disability but also to improve the symptoms of pain and stiffness (54). In order to 
reach this goal, patients are encouraged to perform daily exercises at home and 
weekly group physical therapy, as well as to participate in moderate sport activities 
such as swimming and cycling. These exercises should be continued regularly 
lifelong, and the patient's own efforts are the key to future success (54).
Kraag et al. included 53 AS patients in a RCT comparing a home 
physiotherapy programme combined with patient education versus no intervention at 
all. They demonstrated significantly improved fingertip-to-floor distance and 
function after four months compared to the control group, and concluded that 
physiotherapy with disease education is effective in the treatment of patients with AS
(55). Between four and eight months, fingertip-to-floor distance did not change in 
experimental patients; however, initial improvement achieved was maintained (56).
Thus, an individual home-based or supervised exercise program has shown to be 
better than no intervention.
Hidding et al. (57) and Analay et al. (58) have compared home exercises to 
supervised group exercises. They found that group exercises were superior in
improving movement in the spine and overall well-being, but did not improve self-
reported physical function more than home exercises. Exercises were done for six
weeks (58) to nine months (57), and included strengthening, aerobic exercises, 
hydrotherapy, sports activities and stretching. 
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According to the Best Practice evidence evaluation, there is poor-quality 
evidence for long-term effects on improved mobility following an inpatient 
physiotherapy programme for AS patients. This evaluation is based on the 
retrospective study of Viitanen et al. in 1992 and their 15 months’ follow-up study in 
1995. The efficacy of a three or four-week intensive inpatient physiotherapy 
programme was retrospectively analysed in 505 adult patients with ankylosing 
spondylitis (AS) admitted to a rehabilitation hospital in Finland during a two year
period  (59). Eight different measures of thoracic and spinal mobility were collected 
from the patients' medical records. They demonstrated a 7-37% improvement 
immediately after the rehabilitation period in all mobility measures. Long-term 
effects were studied in 141 of these patients 15 months after the in-patient  
rehabilitation. Only chest expansion CE) and vital capacity (VC) had significantly 
deteriorated from the baseline, while cervical rotation (CR), finger-to-floor distance 
(FFD) and fitness index were still significantly better. Disease duration did not 
influence treatment results. The authors conclude that it is possible by means of 
intensive rehabilitation courses to prevent for more than one year the deterioration of 
spinal function and fitness in AS patients irrespective of disease duration (60).
In 2001, van Tubergen et al. demonstrated that spa-exercise therapy improved
pain and overall well-being more than weekly group exercises alone (61), and that 
the beneficial effects may last for at least 40 weeks. The standardized spa exercise 
therapy of three weeks' duration consisted of group physical therapy, walking, 
correction therapy (lying supine on a bed), hydrotherapy, sports and visits to either 
the Gasteiner Heilstollen in Austria or to the sauna in The Netherlands. After spa-
exercise therapy, all patients followed weekly group physical therapy for another 37 
weeks. The Best Practice evidence evaluation reports medium-quality evidence that 
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spa therapy provides additional effects over self-exercising and group exercising 
alone, based on a review of van Tubergen and Hidding in 2002 (62).
A questionnaire among international ASAS members reveals that the 
awareness of published evidence on physiotherapy in AS are unsatisfactory among 
experts in the field (63). However, according to the Best Practice evidence centre, 
there is good-quality evidence that exercise therapy improves mobility in AS 
patients. This conclusion is based upon the Cochrane review of Dagfinrud et al. (64).
No harm to the patients was reported in any of the studies included in this systematic 
review. And "silver" level evidence (www.cochranemsk.org) was found that 
supported the idea that exercise programs, home-based or supervised, are better than 
no exercise and that they improve movement and physical function. Group exercises 
are better than home exercises; they improve movement and overall well-being. 
Adding a few weeks of exercising at a spa resort to weekly group exercises is better 
than just weekly group exercises. We still need more information about the different 
types of physiotherapy and exercise, and how long, how intensive and how often 
physiotherapy should be done for the most improvement.
POSTPOLIO SYNDROME
Traditionally, energy conservation strategies such as the reduction of activity level 
and increased use of orthopaedic devices and technical aids have been the main goal 
in the rehabilitation of PPS patients (65). Because the initial theories concerning new
weaknesses focused on a dysfunctional or deteriorating motoneuron that was already 
overextended, the preliminary belief among most clinicians was that appropriate
management of these overused motor units was to minimize further overwork. This 
meant either no exercise or, at the most, very limited exercise. It is now clear that 
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new muscle weakness in many persons may have a reversible or “treatable”
component that responds well to certain types of exercises. However, it is also clear 
that the same exercise programme cannot be prescribed to every individual, as the 
extent of involvement, and possibly the cause of new weakness, may vary from 
individual to individual as well as from limb to limb within the same person (66).
Studies of muscle morphology and oxidative capacity in the tibialis anterior
muscle indicate a high muscular activity because of gait and weight bearing. 
Reduced capillary supply in the remaining, hypertrophied muscle fibres and a 
shortage of substrate during muscle work might be of importance in the muscle 
fatigue, myalgia and transient decrease in strength which are commonly occurring 
symptoms in PPS patients (67). However, there are no prospective studies which 
show that increased muscle activity or training lead to loss of muscular strength 
compared with the absence of training or less muscular activity. On the contrary, 
patients who reported regular physical activity had fewer symptoms and a higher 
functional level than physically inactive patients (68).
One randomized controlled trial reports significant improvement in muscular 
strength after a 12 week training programme with isometric contraction of hand 
muscles (69). Nonrandomized trials with training programmes lasting from six weeks 
to seven months involving both isokinetic, isometric and endurance muscular 
training show a significant increase in both isokinetic and isometric muscle strength 
(70-72). No complications or side effects are reported. Hence, there is evidence at 
class II and III (lower class, better evidence) that supervised training programmes 
increase muscle strength in patients with PPS (73).
Ernstoff et al.  report an increase in work performance by a reduction of heart 
rate during exercises; hence, endurance training seems to improve cardiovascular 
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conditioning (Class IV) (72). It should be added that the long-term effects (years) of 
training are not documented and deserve prospective studies.
Even though the efficacy of physiotherapy and regular, physical exercise in 
PPS patients has become more clear, a study of different treatment aspects in 
combination during an intensive, in-patient rehabilitation programme has not yet 
been reported in scientific literature. 
NEUROMUSCULAR DISEASES
Muscle weakness and reduced muscular endurance are prominent symptoms in 
patients having neuromuscular diseases (17;24;25). The role of strengthening 
exercise to potentially improve weakness and the functional abilities of persons with 
neuromuscular diseases is controversial. David D. Kilmer has reviewed the response 
to resistive strengthening exercise training in humans with neuromuscular disease
(74). The studies reviewed were mainly home exercise programmes of durations 
lasting between nine weeks and one year. He was not able to make any conclusions 
about the response in rapidly progressive NMDs, and the response in slowly 
progressive NMDs span from lack of deterioration only to moderate increase (10-
80%) in muscle strength after systematic muscle training.  The largest improvements 
were found in the patients with highest functional level at baseline (74-76). In the 
study of Aitkens et al., a 12-week moderate resistance exercise program was
performed by 27 patients with slowly progressive neuromuscular diseases (NMD) 
and 14 control subjects. They found this intervention to be practical and safe in 
slowly progressive NMD and also that it provided moderate improvement in 
measured strength (75). Modest increases in strength in knee extensors, but a slight 
decrease in elbow flexor strength was observed with a maximal resistance exercise 
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protocol in the study of Kilmer et al.  Thus, a high resistance training programme 
may cause some deleterious effects to diseased skeletal muscle, and only moderate 
resistance training programmes are recommendable in this population (76).
Kilmer concludes his review that resistance exercise may be beneficial if the 
degree of weakness is not severe, and the rate of disease progression is relatively 
slow. However, the studies available have some methodological limitations, such as 
an inadequate number of subjects or a mixed group with different NMDs, ignoring 
the natural history of each disease; therefore future studies are recommended (74).
Individuals with NMD generally represent a very sedentary and 
deconditioned population. Their responses to exercise testing are similar to 
deconditioned able-bodied subjects: lower VO2, minute ventilation, stroke volume, 
cardiac output, work capacity, peripheral blood flow, and strength (77). One of the 
primary questions for researchers and clinicians is whether reduced exercise 
performance is directly due to the muscle or nerve disease through loss of muscle 
tissue or to the effects of physical deconditioning. If it is primarily the latter, 
endurance exercise training may be helpful to reverse untoward effects of the 
deconditioned state.(78)
There are no studies examining aerobic exercise training in the more rapidly
progressive NMDs of amyotrophic lateral sclerosis and Duchenne muscular 
dystrophy (78). In slowly progressive hereditary NMDs, three studies exist that 
combine multiple types of NMD into a group. In Florence and Hagberg, 12 subjects 
performed 12 weeks of cycle ergometry training for 30 minutes, three times per 
week, for 12 wk, at 70% VO2max. This resulted in a 25% increase in maximal 
oxygen uptake, which was similar to control subjects. However, there was significant 
variability between individual subjects (79). Conversely, Wright et al. used a 12
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week home walking programme, 3–4 times a week for 12 weeks at 50–60% heart
rate reserve and found no change in peak VO2, but a reduced heart rate at the same 
submaximal workload supported a training response (80). In an eight week study of 
treadmill exercise in subjects with various dystrophies at 70–85% estimated maximal 
heart rate reserve, Taivassalo et al. demonstrated similar improvements in estimated 
aerobic capacity in both myopathic (15.7%) and control (10.1%) groups. Heart rate 
was significantly reduced at a comparable submaximal workload in the myopathic
group (81).
In summary, this small number of NMD investigations support these 
conclusions: (1) Most studies demonstrate positive response to aerobic exercise 
training, although VO2max may not be affected; (2) cardiorespiratory adaptations to 
submaximal aerobic exercise training are qualitatively similar to adaptations in able-
bodied persons; (3) although short-term adaptations may be demonstrated, the effect 
of long-term aerobic training is unclear and may ultimately be limited by the loss of
muscle mass; and (4) individuals have a variable response to aerobic training,
probably due to effects of the individual disease and level of conditioning at the time 
the study began (78).
Actually, both strengthening exercises and aerobic exercise training are 
supposed to improve health in NMD patients when given individually and with 
moderate intensity, as with the patients having postpolio syndrome. A study of 
different treatment aspects in combination during an intensive, in-patient 
rehabilitation programme for NMD patients has not yet been reported in scientific 
literature. Furthermore, there is a need for randomised controlled trials with a long-
term follow-up.
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CLIMATE THERAPY DEFINITIONS
HYDROTHERAPY
The Encarta encyclopedia defines hydrotherapy as the treatment of diseases by the 
external use of water, for example, by exercising weakened limbs in a pool.
Hydrotherapy uses the physical qualities of water like buoyancy and resistance; the 
temperature may be either cold or warm (82).
THALASSOTHERAPY
The Encarta encyclopedia defines thalassotherapy as sea-water therapy, a therapeutic 
treatment that involves bathing in sea water. 
BALNEOTHERAPY
Balneotherapy is the medical practice of treatment by immersion in baths, especially 
those in spas containing water with a high mineral content according to the Encarta 
encyclopedia’s definition. Verhagen et al. defines balneotherapy in their review as an 
ancient and popular therapy which involves spending time in an indoor pool filled 
with mineral water at a temperature of between 31 to 36 degrees Celsius (88 to 97 
degrees Farenheit). Different types of mineral water may be used in this therapy, for 
example, Dead Sea salt or mineral baths, sulphur baths, and radon-carbon dioxide 
baths (83). Furthermore, Bender et al. define balneotherapy to be the use of thermal 
waters, not only naturally warm (>20°C) but with a significant mineral content. In 
Hungary, a recognised mineral water should have minerals of one g/l or more, but 
no nitrites, nitrates, or bacterial growth (82).
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One of the aims of balneotherapy is to soothe pain and improve joint motion 
and, consequently, to relieve people' suffering and make them feel well (83).
Balneotherapy is either provided as the solitary component of the therapeutic 
approach or in the context of spa therapy (84).
SPA THERAPY
Spa therapy, in addition to balneotherapy, employs various modalities such as
physiotherapy, and even the change in environment and lifestyle (84). Thus, while 
some researchers have regarded balneotherapy and spas as more or less
interchangeable terms (85), others disagree (82). Van Tubergen and Hidding define 
SPA therapy to be a composition of  a wide range of strategies, including 
balneotherapy, hydrotherapy, massages, physical exercises, mud applications and 
relaxation (62).
CLIMATE THERAPY
Climatotherapy is the use of climatic factors for therapy according to Gutenbrunner 
et al. (86). Climatotherapy includes the planned medical application of climatic 
factors that are effective for the prevention or treatment of diseases and the 
improvement of functioning (rehabilitation). Climatotherapy is performed in specific 
climates, e.g. high altitude climates, sea coastal climates, and includes changes of 
climatic environment. Climatic factors with relevance for therapy are radiation
(ultraviolet, light, infrared), thermal stimuli (temperature,
wind, humidity, etc.) and air composition (pO2, therapeutic aerosols, absence of 
pollution and allergens, etc.). Psychological reactions from the experience of 
landscapes may be a factor as well (86).
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When a comprehensive rehabilitation programme is offered in a stable, warm, 
sunny and dry climate, climatotherapy is supposed to be part of the intervention. 
However, the main interventions offered through the Section of Climate Therapy are 
intensive physiotherapy, spa therapy and ”self management” group therapy (87).
CLIMATE MIGHT INFLUENCE 
PREVALENCES AND SYMPTOMS
CLINICAL, RADIOLOGIC, AND SEROLOGIC EXPRESSION OF 
RA
Drosos et al. compared the clinical, radiologic, and serologic expression of 
rheumatoid arthritis (RA) in 108 Greek and 107 British patients with RA (88). They 
demonstrated that the British patients had more severe articular involvement than did 
Greeks, as judged by the duration of morning stiffness, grip strength, and the 
numbers of swollen and tender joints. The British RA patients also had more severe 
joint damage on radiologic examination, and more extraarticular manifestations, 
including rheumatoid nodules and Raynaud's phenomenon. Greek RA patients, 
however, more frequently presented with sicca manifestations and serum antibodies 
to Ro/SS-A. Furthermore, Ro/SS-A antibodies were associated with a high incidence 
of side effects to D-penicillamine only in the Greeks. They concluded that both 
genetic and environmental factors may be responsible for these striking differences 
in disease expression between these two European populations with RA.
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PREVALENCES OF RA
Epidemiological studies show different geographic distributions of a variation of 
diseases. Hameed et al. (89) studied the prevalence of RA amongst Pakistanis living 
in England and in Pakistan, in order to ascertain the  impact of environmental factors 
on the causation of rheumatoid arthritis (RA). They calculated that a standardized 
morbidity ratio (SMR) of RA in England was to be 2.1 compared with Pakistan, a 
difference that was entirely attributable to females. The SMR for women was 3.0 and 
for men 0.86. Furthermore, the colder climate was frequently invoked as a cause of 
more symptoms in England. Thus, several factors may have influenced the 
observation that RA is more common amongst Pakistanis in England compared with 
Pakistanis in Pakistan. An environmental factor cannot be excluded. 
PAIN AND RIGIDITY VARY ACCORDING TO SEASON AND 
WEATHER CONDITIONS 
Despite the pervasiveness of the idea that arthritis is influenced by the weather, 
scientific evidence on the matter is sparse and non-conclusive. However, many 
patients seem to be convinced of this influence. In Aikman’s study of 25 patients 
with RA and/ or osteoarthritis (OA), 92% of participants perceived their symptoms to 
be influenced by the weather, while 48% claimed to be able to predict the weather 
according to their symptoms (90).
AS patients report variation in health status according to season and weather 
conditions. According to the self-administered questionnaire, the AS-AIMS2 
validated for AS, a higher lumbar spine flexibility (Schober index) was associated 
with a higher climatic temperature and lower wind speed. Physical QOL improved in 
the summer, as did Social Interaction in the summer and fall, while Role QOL 
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decreased in the winter (91). Ikuni et al. found definite seasonal differences in RA 
patients, both subjectively and objectively. RA disease activity was higher in spring 
and lower during fall (92).
Smedslund et al. aimed to explore how reported joint pain in patients with 
rheumatoid arthritis (RA) relates to weather and solar variables. The patients differed 
in the variables they responded to and in which direction, except for consistent 
negative associations between pain and ultraviolet light dose, and between pain and 
solar radio flux/sunspot count. The associations were mostly with same-day weather, 
but also lagged up to three days. Thus, they were not able to fit a statistically 
significant model at the group level. The conclusion that weather sensitivity seems to 
be a continuum and a highly individual phenomenon in patients with RA may 
explain the wide gap between the patients’ conviction and the scientists’ difficulty in 
finding evidence of the climatic influence on arthritic symptoms (93).
While the majority of RA patients report that their pain is influenced by the 
weather, studies examining the impact of weather on RA pain have yielded equivocal 
results. It is not clear from the existing studies if the mixed results are due to limited 
statistical power (e.g. small sample sizes and restricted variability in weather indices) 
or the failure to consider individual differences.
THE INFLUENCE OF TEMPERATURE, ATMOSPHERIC 
PRESSURE AND HUMIDITY ON PAIN AND RIGIDITY
PAIN
Low temperature and low atmospheric pressure increase the risk of joint pain in 
rheumatic patients (94) and intensify pain in arthritic rats (95). Sato et al. examined 
the effects of change in meteorological parametres on pain-related behaviors in a 
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simulated arthritic condition exposed to low barometric pressure (20 mmHg below 
the natural atmospheric pressure) and low ambient temperature (7 degrees C lower 
than 22 degrees C) in a climate-controlled room. When the arthritic rats were 
exposed to these environments, the already-increased number of hindpaw 
withdrawals in response to noxious mechanical stimulation (hyperalgesia) was 
further increased and a hindpaw withdrawal response to innocuous mechanical 
stimulation (allodynia) began to occur. Such exposures did not influence any of the 
pain-related behaviors of the control rats. These results show that lowering 
barometric pressure and ambient temperature within the range of natural 
environmental fluctuation can intensify pain in arthritic rats (95).
The correlation between low temperature and low atmospheric pressure and 
increased joint pain are demonstrated in different rheumatic patient groups. Guedj 
and Weinberger found that pain was positively affected by barometric pressure and 
temperature in RA, by temperature, rain, and barometric pressure in osteoarthritis 
(OA), and by barometric pressure in fibromyalgia. Women were more sensitive to 
weather than men (62% v 37%) (96).
Gorin et al. studied 75 RA patients recording their daily pain severity for 75 
consecutive days (97). They demonstrated highest pain levels on cold, overcast days 
and following days with high barometric pressure. Pain levels also increased as a 
function of change in relative humidity from one day to the next. Individual 
difference analyses revealed significant variability between patients in their weather 
sensitivity patterns. In general, patients with higher levels of self-reported pain 
demonstrated more weather sensitivity. When considering the magnitude of these 
effects, however, weather variables accounted for only a small amount of change in 
pain scores. This pattern was true even for patients with the most pronounced pain-
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weather relationships. Therefore, although weather sensitivity was found, the effect 
sizes were not clinically meaningful (97).
PAIN AND RIGIDITY
Aikman sought to establish a possible relationship between the pain and rigidity of 
arthritis and the weather variables of temperature, relative humidity, barometric 
pressure, wind speed and precipitation. Mean pain and rigidity scores for each time 
of each day were found to be correlated with the meteorological data. Correlations 
between mean symptoms and temperature and relative humidity were significant. 
Stepwise multiple regression analysis indicated that meteorological variables and 
time of day accounted for 38% of the variance in mean pain and 20% of the variance 
in mean rigidity when data of all months were considered. Hence, the results suggest 
(1) decreased temperature is associated with both increased pain and increased 
rigidity and (2) increased relative humidity is associated with increased pain and 
rigidity in arthritis sufferers (90).
According to Patberg and Rasker’s review, RA variables are positively 
correlated with the humidity of the microclimate at the patient's skin, and the classic 
opinion, "Cold and wet is bad, warm and dry is good for RA patients," seems to be 
true only as far as humidity is concerned (98).
SECTION FOR CLIMATE THERAPY, 
HISTORY AND PRESENT PRACTICE
In Norway, it has been a tradition to admit patients with rheumatic diseases to 
comprehensive rehabilitation in a warm climate (87). The very first patients were 
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sent in 1976 because of low treatment capacity for rheumatoid patients in Norway. 
This tradition was continued for three to five years at a time until 1984, when it was 
defined as a separate item on the national budget. Initially, the arrangement was
considered as an alternative to existing hospital treatment for patients with rheumatic 
diseases. Gradually, as departments of rheumatology became more numerous in 
Norway, warm-climate rehabilitation increasingly became a supplementary regimen. 
In 1997, the Norwegian Parliament decided to make this arrangement a permanent 
therapeutic option (99). This decision was based on documented efficacy of 
physiotherapy in warm climate and a relatively low cost. In 2000, an official 
Norwegian Report called “Treatment Abroad: a Public Responsibility?” was 
published (99). This report examined the concept, the rationale for and existing 
evidence of additional efficacy of physiotherapy in warm climates, and generated 
some guidelines for future practice. From 2001 to date, this therapeutic option has 
been administered by the Section for Climate Therapy at the Department of 
Rheumatology at Oslo University Hospital, Rikshospitalet. 
The rehabilitation programme is generally provided at selected institutions in 
the Mediterranean area with warm and stable climatic conditions, by 
multidisciplinary rheumatology teams for periods of four weeks. The therapy 
consists of intensive physiotherapy, spa therapy and ”self management” group 
therapy. When a comprehensive rehabilitation programme is offered in a stable, 
warm, sunny and dry climate, climatotherapy is supposed to be part of the 
intervention (86).
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REHABILITATION IN WARM 
CLIMATE; WHAT IS THE 
EVIDENCE?
Studies evaluating the efficacy of inpatient rehabilitation in a warm climate for 
patients with rheumatic diseases are presented in Table 5. The intervention given in 
these studies meets the definition of comprehensive rehabilitation given in the second 
subheading of this chapter. 
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Table 5.  Studies of 3-6 weeks inpatient rehabilitation in a warm climate. *In the 
RCTs, only the outcome measures with significant difference between warm and 
cold climate are given. 
Authors, 
year of 
publicatio
n
Diagnosis, 
number of 
patients (n)
Design,
location
Outcome measures 
with  immediate 
significant 
improvements*
Follow-up  (post 
discharge)
Johansson 
and
Sullivan 
(100)
1975
RA 
(females), 
n=79
RCT,
crossover, 
Spain vs. 
Sweden 
(outpatient)
Disease activity
(Lansbury, s
Rheumatoid Activity 
Index and Salicylate 
need) 
Physical function
(ROM and grip 
strength) 
Patient’s 
assessments
four months: 
Uncertain efficacy
Kapstad 
and Noreik 
(101)
1994
RA and AS, 
n=130
Uncontrolled, 
prospective, 
Turkey
Patient’s 
assessments
three months: 
sustained efficacy 
among the most 
affected patients 
at baseline 
Hafström 
(102)
1997
RA and 
SpA 
n=149
Uncontrolled, 
prospective, 
Montenegro, 
Spain and 
Canarias
Patient’s 
assessments:
Physical function 
(HAQ) and VAS 
global
three and six
months: 
sustained, but 
reduced efficacy
Cronstedt 
and
Stenström 
(103)
2002
SpA, n=48 Uncontrolled, 
prospective, 
Canarias
Mobility (BASMI)
Patient’s 
assessments:
Disease activity 
(BASDAI), Physical 
function (BASFI) and 
VAS global (BASG-1)
three weeks 
(without BASMI): 
sustained efficacy 
in all outcome 
measures, 
three months: 
sustained 
improvement in 
BASDAI og 
BASG-1 only
Hashkes 
(104)
2002
RA, AS and 
PsA (RA or 
AS like), 
n=136
Uncontrolled, 
prospective,
Israel
Mobility (Schober’s 
test, OWD and FFD)
Improvement 
criteria:
57% ACR20 
responders
60%  ASAS20 
responders
None
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Hafström 
and
Hallengren 
(105)
2003
RA/JRA 
and SpA, 
n=93
Uncontrolled, 
prospective,
Israel and 
Canarias
Patient’s 
assessments:
Physical function 
(HAQ) Symptoms 
(VAS pain and VAS 
global) 
Health-related quality 
of life (NHP)
three and six
months: 
sustained efficacy 
in all outcome 
measures
RA; rheumatoid arthritis, RCT; randomised controlled trial, ROM; range of motion, AS;
ankylosing spondylitis, SpA; spondylarthropathy, HAQ; Stanford Health Assessment 
Questionnaire, VAS;visual analogue scale, BASMI; Bath Ankylosing Spondylitis 
Metrology Index, BASDAI; Bath Ankylosing Spondylitis Disease Activity Index, BASFI;
Bath Ankylosing Spondylitis Functional Index, BAS-G; Bath Ankylosing Spondylitis 
Patient Global Score, PsA; psoriasisarthritis, ACR; American College of Rheumatology, 
ASAS; The ASsessments in Ankylosing Spondylitis working group, OWD; Occiput-Wall 
Distance, FFD; Finger-Floor Distance, JRA; juvenile rheumatoid arthritis, 
NHP;Nottingham Health Profile
RHEUMATOID ARTHRITIS
The only reported controlled study of the outcome of a rehabilitation programme in a 
warm climate for RA patients showed that physiotherapy in warm climate was 
superior to outpatient treatment in Sweden immediately after the treatment period, 
whereas the long-term effect was uncertain (100). Some uncontrolled studies of 
physiotherapy in a warm climate of three to six weeks’ duration have reported 
sustained improvements in patients’ self-reports after three to six months
(101;102;105). Hashkes achieved 57% ACR20 responders according to the 
American College of Rheumatology (ACR) response definition (106), but his 
uncontrolled study did not include any long-term follow-up (104).
ANKYLOSING SPONDYLITIS
Some uncontrolled studies of physiotherapy of three to six weeks duration in a warm 
climate have reported sustained improvements in self-reported health status after 
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three to six months (101-103;105). Hashkes found 60% responders to climatic 
therapy using the ASAS criteria for improvement (IC) (107), but this study was 
uncontrolled and did not include any follow-up (104).
POSTPOLIO SYNDROME
Norwegians with PPS have subjectively reported that staying in countries with 
warmer climates for a period of time has shown positive effects on their health 
problems (108). However, there has been a lack of scientific publications on 
treatment of PPS patients in warmer climates.
NEUROMUSCULAR DISEASES 
Individuals with NMDs also report subjectively positive effects of physiotherapy in a 
warm climate setting. One randomised, controlled trial of a four-week rehabilitation 
programme for patients with neuromuscular diseases in warm contra cold climate has 
been accomplished. This study demonstrated immediate effects in patient’s 
assessments after physiotherapy in warm climate only, but sustained improvements 
in physical tests three months after intervention in both climate groups. No 
significant difference was found between the improvements in warm and cold 
climates, but the improvements in warm climates tended to sustain longer, even six 
months after the rehabilitation period (109;110).
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AIMS OF THE STUDIES
The overall aim of our studies was to investigate the influence of a four week 
intensive rehabilitation programme on the health status of patients having chronic 
rheumatic or neurological diseases, and to ascertain whether the efficacy of this 
intervention varies according to warm and cold climate settings.
Study 1 (Papers 1 and 2):
We wanted to investigate if a four week rehabilitation programme influences health
status for patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), 
and to compare the eventual effect of this intervention given in a Mediterranean or a
Norwegian climate. We intended to focus on:
 internationally accepted core sets and improvement criteria and 
objective tests of physical capacity.
 a 3(-6) months follow-up aspect. 
Study 2 and 3 (Papers 3 and 4):
We wanted to investigate if a four week rehabilitation programme in a cold climate 
(Norway) influences health status for patients with postpolio syndrome (Paper 3), 
and if a four week rehabilitation programme in a warm climate influences health
status for patients with postpolio syndrome (Paper 3) and neuromuscular diseases 
(Paper 4). We intended to focus on:
 the physical, psychological and social dimensions of health according to 
WHO’s International Classification of Functioning, Disability and Health.
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 a follow-up after 6 months for the PPS and after 3 months for the NM 
study.
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METHODS
DESIGN OF THE STUDIES
The three studies of this thesis are designed as randomised controlled trials (RCTs). 
Long-term effect was defined as a sustained effect in at least three months after the 
four week rehabilitation programme. Design, number of participants (n), and the 
centres attended in the different studies are presented in Table 6.
Table 6.  Design, number of participants (n), and the centres attended in the different 
studies
Diagno
sis
Design Follow-
up
n Centres attended
RA and 
AS
RCT, 2 groups:
warm versus 
cold climate
three
and six
months
124(RA)
/
107(AS)
Warm climate:
Institute Igalo in Montenegro, or 
Balcova Thermal Therapy Centre, 
Izmir, Turkey
Norway:
North Norway Rehabilitation Centre 
(RNNK), Tromsø, or
Skogli Rehabilitation Centre AS, 
Lillehammer 
PPS RCT, 3 groups: 
warm versus 
cold climate 
versus control
three
and six
months
88 Warm climate:
Clinica Vintersol, Tenerife
Norway:
Hokksund Kurbad, Hokksund or
Vikersund Kurbad, Vikersund
NM RCT, crossover, 
2 groups: warm 
climate versus  
control
three
months* 
60 Warm climate:
Reuma-Sol Centre, Costa Blanca, 
Spain
RA, rheumatoid arthritis; AS, ankylosing spondylitis; PPS, postpolio syndrome; NM, 
neuromuscular diseases; RCT, randomised, controlled trial; n, number of participants. * a 
second baseline at 11 months after the first intervention
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PATIENT FLOW
FLOW OF THE PARTICIPANTS IN THE RA STUDY
The 124 participants of this study were recruited from the population of adult 
patients with rheumatic diseases who applied for a four week rehabilitation 
programme either in a Mediterranean country through the Section for Climate 
Therapy at Rikshospitalet in Oslo or at the North Norway Rehabilitation Centre 
(RNNK) in Tromsø.
Figure 1. Summary of patient disposition in the rheumatoid arthritis patients, non-
participants in italics (n= 167+19+43). * The patients excluded did not meet the 
American College of Rheumatology (ACR) classification criteria of RA (1987) at the 
first medical examination (2).
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FLOW OF THE PARTICIPANTS IN THE AS STUDY
The 107 AS patients were recruited from the applicants to a rehabilitation 
programme in a Mediterranean country, administered by the Section for Climate 
Therapy at Oslo University Hospital, Rikshospitalet or from the applicants to the 
North Norway Rehabilitation Centre (RNNK) in Tromsø.
167 patients would not 
participate or did not
answer our request
186 patients 
randomised
95 assigned to treatment in 
Norway
91 assigned to treatment in 
Mediterranean climate
19 discontinued the study
 12 withdrawn after 
randomisation before 
treatment 
 4 lost to follow up at 
control after three months
 3 were excluded from the 
study after completion *
72 (79% of the 
randomised) 
completed the study
52 (55% of the 
randomised) 
completed the study
43 discontinued the study
 29 withdrawn after 
randomisation before 
treatment
 2 lost to follow up at 
control after three months
 12 were excluded from the 
study after completion *
353 invited to 
participate
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Figure 2. Summary of patient disposition in the ankylosing spondylitis patients, non-
participants in italics, n=218 (171+10+1+1+28+2+5). * The patients excluded
from the analysis did not meet the Modified New York Criteria for Ankylosing 
Spondylitis (1984) at the first medical examination (9).
Assessed to be eligible and 
invited to participate (n= 325 )
Declined to participate or didn’t 
answer our request (n= 171)
Analysed (n= 65)
 Excluded from analysis (did not meet the 
diagnostic criteria for Ankylosing Spondylitis*) 
(n= 1 )
Lost to follow-up at control after three months    
(n= 1)
Allocated to intervention in Mediterranean 
climate (n= 77 )
 Received allocated intervention (n= 67) 
 Did not receive allocated intervention (chose 
not to participate after randomisation) (n= 10 )
Lost to follow-up at control after three months    
(n= 2)
Allocated to intervention in Norway (n= 77 ) 
 Received allocated intervention (n= 49)
 Did not receive allocated intervention (chose 
not to participate after randomisation) (n= 28)
Analysed  (n= 42)
 Excluded from analysis (did not meet the 
diagnostic criteria for Ankylosing Spondylitis*) 
(n= 5 )
ALLOCATION 
ANALYSIS 
FOLLOW-UP 
Randomised (n= 154 )
ENROLLMENT 
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FLOW OF THE PARTICIPANTS IN THE PPS STUDY
The 88 PPS patients in this study were recruited from the previously registered 
patients with PPS at Sunnaas Rehabilitation Hospital. 
Figure 3. Summary of patient disposition in the PPS study.
Assessed for eligibility (n=319)
Excluded (n= 213)
 Did not meet inclusion criteria 
(n= 144)
 Declined to participate (n= 66)
 Other reasons (n= 3)
Analysed (n= 30)
 Excluded from analysis (n= 0)
Lost to follow-up (n= 0)
Discontinued intervention (n= 0)
Allocated to intervention in warm 
climate (n= 37)
 Received allocated intervention (n=
30) 
 Did not receive allocated 
intervention (chose not to 
participate after randomisation, 
n= 7)
Lost to follow-up (n= 0)
Discontinued 
intervention (n= 0)
Allocated to control group (n= 
31)  Remained (n= 29)
 Did not remain in the control 
group (chose not to participate 
after randomisation, n= 2)
Analysed (n= 29)
 Excluded from analysis 
(n= 0)
ANALYSIS 
Randomized (n= 106)
ENROLLMENT 
Allocated to intervention in 
Norway (n= 38)
 Received allocated 
intervention (n= 29)
 Did not receive allocated 
intervention (chose not to 
participate after randomisation, 
n= 8)
Lost to follow-up (n= 0)
Discontinued intervention 
(psychological reason) (n=1)
Analysed (n= 29)
 Excluded from analysis (n= 0)
ALLOCATION 
FOLLOW-UP 
56
FLOW OF THE PARTICIPANTS IN THE NMD STUDY
The 60 participants of this study were recruited through advertisements in six daily 
newspapers and the Norwegian neuromuscular organization’s newsletter, or through 
the local groups of the Norwegian neuromuscular organization or one of the two 
university hospitals in Norway with special units for neuromuscular diseases (Oslo 
University Hospital, Rikshospitalet and the University Hospital of North Norway). 
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Figure 4. Flow of the participants through each stage of the cross-over designed trial 
with patients having neuromuscular diseases.
Completed baseline assessment at Sunnaas 
Rehabilitation Hospital (questionnaires and physical 
tests)(n=60)
Stratified randomization into one of two groups. 
Group A, first period in Spain, Group B, first period 
in Norway. 
One drop-out due to personal problems
(n=28)
60 participants (n=60) was included and consented
Allocated in Group A:
- Four weeks rehabilitation in Spain 
(n=30)
* Withdrew due to family problems (n=1)
-Completed intervention (n=29)
Allocated in Group B:
-Daily life in Norway without 
intervention (n=30)
- Completed the period (n=30)
Group B:
-Four weeks rehabilitation in Spain
(n=25)
* Withdrew before start: due to delivery 
(n=1), poor health condition (n=1), 
responsibilities at home (n=1), planned 
vacation (n=1), anxiety of insufficient 
assistance (n=1)
-Completed intervention (n=25)
Group A:
- Daily life in Norway, without 
intervention ( n=28)
- Completed the period (n=28)
Assessment of all participants three months after 
intervention (n=53¹)
¹ Four persons answered the questionnaires but didn’t attend 
physical testing.
Assessment of all participants three months after 
intervention (n=58¹)
¹ Four persons answered the questionnaires but didn’t attend 
physical testing.
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PATIENT CHARACTERISTICS
Number, female sex proportion and mean age of the participants in the RA, AS, PPS 
and NMD studies are given in Table 7.
Table 7. Number, female sex proportion and mean age of the participants in 
the RA, AS, PPS and NMD studies
n in warm 
climate/cold 
climate/control
Female sex, n (%) 
in warm/cold 
climate/control
Age, years, mean (SD) in 
warm/cold climate/control
RA 72/52 56(78)/ 41(79) 53(9)/ 53(10)
AS 65/42 27(42)/ 19(45) 48(10)/ 51(8)
PPS 30/29/29 22(73)/ 20(69)/
19(66)
57(8)/57(8)/59(9)
NMD 60 38(63) 44(12)
INTERVENTION 
RHEUMATOID ARTHRITIS AND ANKYLOSING 
SPONDYLITIS STUDY 
The participants followed the regular rehabilitation programme given to RA and AS
patients at the four different centres attended (Table x). The main components of the 
therapy offered were individualised physiotherapy with exercises, group exercises, 
passive therapy, relaxation, and patient education. 
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Active physiotherapy. This included both individualised physiotherapy with 
exercises and group exercises. The individualised physiotherapy was given once a 
day either on the couch, in the fitness department using specially constructed 
equipments, or in the pool. The group training (eight to 15 patients) was given twice 
a day, once in the gym and once in a temperature-controlled swimming pool. During 
one week, the patients had a total of 12-15 obligatory sessions, active physiotherapy 
of 20-45 minute duration in the Mediterranean climate and 15-16 sessions of 30-60
minute duration in Norway. The exercise therapy aimed at increasing endurance, 
mobility and strength. While the Norwegian programme included more endurance 
training, the Mediterranean programme had more focus on mobility. At all treatment 
centres, the patients had different opportunities for additional, voluntary, physical 
activities either in groups or individually. 
Passive therapy comprised of thermotherapy, massage and electrotherapy. At 
both rehabilitation centres in warm climate (thermo-)mineral water was used in the 
swimming pools, bubble baths and for underwater massage; hence balneotherapy 
was part of the programme. The mud is administered as warm packets or filled in a 
bath tub and mixed with mineral water. A wide range of electrotherapy was offered 
for local soft tissue pain and oedema. It was the doctor who prescribed the type and 
amount of passive therapy. At both rehabilitation centres in the Mediterranean 
climate, they usually prescribed two passive treatments of 10-15 minutes a day for 
each patient, whereas the patients in Norway only got passive therapy when they had 
a special need for it. 
The different rehabilitation centres had different specialities, and this was 
especially reflected in the passive therapy offered. Balcova Thermal has two thermo 
mineral water springs which has been used in spa therapy since ancient times
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(“Agamemnon spring”). Institute Igalo has a mineral water spring as well and 
radioactive mud coming from the river of Sutorina which they use in therapy. 
Relaxation. The programme included classes in relaxation, organized as 30-
45 minute supervised relaxation two to four times a week at Lillehammer, Tromsø 
and Balcova. At Institute Igalo, activities like yoga and tai chi were offered. 
Patient education. Disease-specific lectures about RA were given at all four 
centres focusing on diet, physical activity, self efficacy, coping techniques and 
advice related to general health. 
Voluntary physical activities. When the compulsory therapy of the day was 
finished, the patients had different opportunities for voluntary physical activities such 
as arranged hiking trips, ball games and self-training in the pool or fitness 
department. The programme varied across the different therapy centres, and the 
proportion of attending patients was higher at the Norwegian centres. 
POSTPOLIO STUDY
The three institutions involved offered their ordinary programmes adapted for PPS 
subjects during the intervention period. However, to ensure similar treatment at the 
three centres, professionals from Sunnaas Rehabilitation Hospital discussed and 
repeated the main principles for treatment of PPS subjects with the professionals at 
the involved rehabilitation centres. The main components of the therapy offered were 
active physiotherapy in groups, individualised physiotherapy with exercises and 
passive therapy, relaxation, patient education and occupational therapy advices. 
Active physiotherapy. This included group exercises which were given twice 
a day, once in the gym (sitting on a chair) and once in a temperature-controlled 
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swimming pool. Most subjects attended daily treatment in the swimming pool (45 
minutes) and physiotherapy (30 minutes). In addition, each subject was prescribed an 
individually-adapted training program based on his or her functional level. 
Passive therapy. The individualised physiotherapy was given either on the 
couch or in the fitness department using specially constructed equipments. Apart 
from supervision in active exercises, this was a passive form of therapy: soft tissue 
treatment, stretching, thermotherapy, electrotherapy or acupuncture. A session was 
30 minutes, five times a week at Clinica Vintersol, four times a week at Hokksund 
Kurbad, and three to five times a week at Vintersol Kurbad.
Relaxation. The programmes included classes in relaxation, organized as 
supervised relaxation at Hokksund Kurbad and Clinica Vintersol, and as autogenic 
training at Vikersund Kurbad. 
Patient education focusing on physical activity, self efficacy, ergonomics and 
advice related to energy conservation was given once a week at Vikersund Kurbad. 
Focus group interviews were performed at Hokksund and Vintersol Kurbad one to 
two times a week and once in the third week for all patients by the study team. 
Occupational therapy advice was given when needed at Vikersund Kurbad
and Clinica Vintersol and ergonomic group training for hand function were offered at 
Clinica Vintersol as well.
Voluntary physical activities such as self-training in the pool or fitness 
department, arranged hiking trips or ball games were offered at all treatment centres. 
STUDY OF NEUROMUSCULAR DISEASES
The treatment programme comprised of strength and endurance training at low to 
moderate intensities, as well as exercises to improve stability, balance and 
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coordination. To be able to give an adapted level of training, the participants were 
divided into three different training groups based on the clinical evaluation of 
physical function by the physiotherapists. 
Active physiotherapy. This included group exercises that were given twice a 
day; in the gym (60 min) and in a temperature-controlled swimming pool (60 min). 
In addition, each patient was prescribed an individually adapted training program 
based on his or her functional level. 
Individualised physiotherapy was given on request. An average of four 
treatments was given to each participant during one week. This comprised both 
supervision in self-training and transfer techniques and more passive therapies like 
soft tissue treatment and stretching. 
The programmes included one class in relaxation each week. Patient 
education was given focusing on the included diagnosis and corresponding treatment 
recommendations.
Voluntary physical activities like Nordic Walking and ball games were 
arranged. The organisation of the daily programme gave the participants opportunity 
to recover perform exercises or take a walk on their own according to their 
individual needs.
CLIMATE
Apart from Clinica Vintersol at Tenerife, which is a Canary Island located on the 
west coast of Africa, all treatment centres in our studies were located by the 
Mediterranean Sea and are therefore supposed to have a Mediterranean climate.
Institute Igalo is located at the Montenegrian coastline, Balcova Thermal Therapy 
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Centre in Izmir in Turkey and Reuma-Sol Centre on the coast of Spain (Costa 
Blanca).
In the RA and AS study, the patients living in the northern parts of Norway 
received their rehabilitation programme at RNNK in Tromsø, which is located on the 
Northern Norway coastline, while the patients living in the southern parts received 
their rehabilitation programme at Skogli in Lillehammer, which is located in the 
inland area. Norwegian treatment centres attended in the PPS study, Hokksund og 
Vikersund Kurbad, were located at the inland area of eastern Norway. Mean 
temperature and number of “rainy days” during each four week rehabilitation period 
at the sites of intervention in the RA, AS, PPS and NMD (111) studies are presented 
in Table 8.
Table 8.  Mean temperature and number of “rainy days” * during each 4-week 
rehabilitation period at the sites of intervention in the RA, AS, PPS and NMD 
studies  
Diagnosis Climate group Centre Mean temp °C Rainy 
days* (n)
Rheumatoid Arthritis Warm Climate Igalo 24 2
Izmir 20 1
Cold Climate Lillehammer 1 9
Tromsø 6 13
Ankylosing 
Spondylitis
Warm Climate Igalo 24 2
Izmir 20 1
Cold Climate Lillehammer 2 8
Tromsø 3 12
Postpolio Syndrome Warm Climate Tenerife 25 mostly dry 
and sunny
Cold Climate/
Control
0 mainly 
rainy or 
snowy
Neuromuscular 
Diseases
Warm Climate 
(1st period)
Spain 25 4
(2nd period) Spain 24 3
* days with precipitation above 1.0mm 
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OUTCOME MEASURES
The physiotherapy programmes offered to the different patient groups of our studies 
all aimed at improvement of, or prevention of, the deterioration in physical 
functioning. Thus, tests of physical capacity became appropriate and had common 
outcome measures. The Six Minute Walk Test (6MWT) was measured in all patient 
groups. In addition, questionnaires about physical function were also used in all 
patient groups. Modified Health Assessment Questionnaire (MHAQ) was measured 
in the RA patients, Bath Ankylosing Spondylitis Functional Index (BASFI) in the AS 
patients, and Sunnaas ADL index and Rivermead Mobility Index in the patients with 
PPS or NMD. MHAQ and BASFI are disease specific instruments designed for the 
typical problem areas in RA and AS patients, respectively, thus they are naturally not 
as comparable as a generic questionnaire or an endurance test would be. 
Pain measured on a visual analogue scale (VAS) was another common 
parametre, reflecting pain as a common symptom in all patient groups described in 
this thesis.
PREDEFINED IMPROVEMENT CRITERIAS
In rheumatology, predefined criteria are developed to measure disease activity and 
improvement. These criteria are defined by international accepted working groups, 
and are supposed to reflect common, clinical signs and complaints in the actual 
patient group. Thus, the outcome measures chosen to evaluate the efficacy of 
treatment in RA patients in our study were designed to fit into the 28-Joint Disease 
Activity Score (DAS28) -calculator of disease activity, and the American College of 
Rheumatology improvement criteria (ACR 20% or 50%). Similarly, the ASsessments 
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in Ankylosing Spondylitis working group’s Improvement Criteria (ASAS-IC) were 
used to measure treatment response in the AS patients (107). In addition, spinal 
mobility tests were taken to concur with the ASAS international working group’s 
core set for physical therapy (PT) interventions, which includes tests of spinal 
mobility in addition to the ASAS-IC parametres (Figure 5) (53).
Figure 5.  The ASAS international working group’s core set for physical therapy 
(PT) interventions used for patients with ankylosing spondylitis.
DAS28 AND ACR CRITERIA
For RA patients, the 28-Joint Disease Activity Score (DAS28) was calculated from 
the following formula using the patient's assessment of disease activity (100mm 
VAS) instead of general health (GH): DAS28 = 0.56 * sqrt(tender28) + 0.28 * 
sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH (112) das-score.nl .
ACR20 and ACR50 responses were calculated based on changes in the 
components of the ACR-core set. To fulfil the ACR20 improvement criteria, a RA 
patient has to achieve greater than or equal to 20% improvement in tender joint 
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counts (TJC) and swollen joint counts (SJC) and greater than or equal to 20% 
improvement in at least three of the following five ACR core set measures: pain, 
patient and physician global assessments, self-assessed physical disability, and 
acutephase reactant. An ACR50 response reflects a 50% improvement in the same 
parametres (106).
ASAS IMPROVEMENT CRITERIA AND ASAS CORE SETS
To attain an ASAS20 improvement, an AS patient has to achieve >20% relative 
improvement and an absolute improvement of >1 unit (on a scale of 0-10) in three or 
more of the following four domains: patient’s global assessment, patient’s
perception of pain (question two of the BASDAI), inflammation (mean of questions
five and six of the BASDAI), and function (BASFI), with no worsening by >20% 
and >1 unit in the remaining domain (107). ASAS40 improvement was defined as 
attaining a >40% relative improvement and an absolute improvement of >2 units in 
three or more of the four domains, with no deterioration from the baseline in the 
remaining domain (113).
THE ICF PERSPECTIVE 
The studies of postpolio syndrome and neuromuscular diseases were designed at 
Sunnaas Rehabilitation Hospital (SunRH), thus the rehabilitation aspect leads to a 
selection of outcome measures in an “International Classification of Functioning, 
Disability and Health” (ICF) perspective. The ICF is a classification of health and 
health-related domains. These domains are classified from body, individual and 
societal perspectives by means of two lists:  a list of body functions and structure, 
and a list of domains of activity and participation. Since an individual’s functioning 
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and disability occurs in a context, the ICF also includes a list of environmental 
factors.”(Figure 6) http://www.who.int/classifications/icf/en/
ICF belongs to the WHO family of international classifications, the best 
known member of which is the ICD-10 (the International Statistical Classification of
Diseases and Related Health Problems). ICD-10 gives users an etiological
framework for the classification, by diagnosis, of diseases, disorders and other
health conditions. By contrast, ICF classifies functioning and disability
associated with health conditions. The ICD-10 and ICF are therefore
complementary, and users are encouraged to use them together to create a
broader and more meaningful picture of the experience of health of individuals
and populations. (114;115)
Figure 6:
The International Classification of Functioning, Disability and Health (ICF)
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In Table 9, the outcome measures used in the two studies of neurological diseases are 
coded in an ICF perspective. Some multidimensional outcome measures might cover 
more than one dimension of health, and then the dimension that has been focused on 
in our setting is chosen.
Table 9.  Outcome measures in a ICF perspective
Variables ICF code PPS NM
Body functions and structures 
Pain
10cm or 100mmVAS (116)
1-6 Likert scale
b280 Sensation of pain
X
X
X
Fatigue
Fatigue Severity Scale (117;118)
b130 Energy and drive functions
X X
Subjective health complaints 
(SHC), (=Ursin Holger 
Inventorium) (119)
Chapter b2 More sensory 
functions and pain X X
Handgrip strength
Grippit Deluxe Hand Dynano-
meter Jamar Limited (120)
b730 Muscle power
X
Lung function
Micro Plus Spirometer (121)
b440 Respiration functions
X
Activity
Walking endurance 
Six Minute Walk Test (6MWT) 
(122;123)
b4550 General physical 
endurance and  
d450 Walking
X X
Fast walking (measured by a 20 
m walking test) (122;123)
b770 Gait pattern functions and 
d450 Walking X X
Mobility/ balance 
Timed Up and Go (TUG) (124)
d420 Transferring oneself, d450 
Walking X X
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Rivermead Mobility Index (125)
(122)
d410 Changing basic body 
position
X X
Activities of daily life
Sunnaas ADL index (126)
b620 Urinary function 
d455 Moving around 
d510 Washing oneself 
d520 Toileting
d540 Dressing
d550 Eating
d560 Drinking 
d630 Preparing meals
d640 Doing housework and d399 
Communication, unspecified
X
Participation
Quality of life
Life Satisfaction Scale (LSS) 
(127;128)
d750 Informal, social relationship 
d760 Family relationship
d770 Intimate relationship d870 
Economic self-sufficiency d859 
Work and employment
X X
Mood
Profile of Mood States (POMS) 
(129)
b152 Emotional functions
b1263 Psychic stability X
Depression
Beck’s Depression Inventory (BDI) 
(130)
B152 Emotional functions, b180 
Experience of self and time 
functions
X
From the ICF checklist: b= Impairments are problems in body function as a significant 
deviation or loss, d= Activity limitations are difficulties an individual may have in 
executing activities. Participation restrictions are problems an individual may have in 
involvement in life situations. 
ICF core sets for rheumatoid arthritis have been defined (131) and tested for  
reliability (132). Stucki et al. focus on ICF’s value and application in rehabilitation 
medicine (133), stating that its success will depend on the compatibility with current 
measures used in rehabilitation medicine (133). The outcome measures used in the 
RA and AS study of this thesis could be coded into an ICF perspective as well. But 
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since the results in these patients have been presented according to the predefined 
improvement criteria, we chose to hold on to that disposition.
STATISTICAL ANALYSES
Statistical analyses were undertaken with the SPSS (Statistical Package for Social 
Sciences) program, versions 13.0 (RA and AS), 12.0 (NMD) and 7.5 (PPS). 
Continual data was presented as mean and standard deviation (SD) or median and 
25th, 75th centiles (quartiles) according to whether the observations showed normal 
distribution. Number of patients and percentage of total number were given for the 
categorical data. 
In all studies of this thesis, we did statistical analysis for the comparison of 
two groups. To compare the non-participants with the participants and the different 
treatment or control groups, we used the Pearson Chi-Square Test if the observations 
were of categorical nature and Fisher’s Exact Test if expected frequency was below 
five in more than 25% of the cells. If the observations were of continual nature, we 
used the Independent Samples T-Test for observations with normal distribution and 
presented the results given for equal variances not assumed if p<0.05 at Levene’s 
Test for Equality of Variances. The Mann Whitney U-Test was done if the continual 
observations did not show normal distribution.
In the RA, AS and NMD studies, the clinical response was given as the mean 
difference from baseline with corresponding SD, or median difference from baseline 
with corresponding quartiles according to whether the differences showed normal 
distribution or not (Papers 1, 2 and 4). In the PPS study, the values at each time point 
were presented (Paper 3). In the NMD study, the 95% confidence intervals were 
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given for the differences in changes from baseline between the groups (Table II, 
Paper 4).
For the normal distributed mean or mean difference, Paired Samples T-Test 
and Independent Samples T-Test were used for within group and between groups 
analysis, respectively. When the median or the median difference have been 
presented, the Wilcoxon Signed Rank test and Mann-Whitney U-test have been used 
for within group and between groups analysis, respectively.
The data from the cross-over study (NMD) were analysed as described in 
Altman; practical statistics for medical research ( page 467-471) (134). No 
significant period or carry-over effects were found for the changes, and the analyses 
were therefore performed on the material as a whole, not regarding the order in
which intervention was given (Paper 4). 
The chosen level of significance was probability (p) values < 0.05.
In the thesis, we calculated the effect sizes (ES) of the attained improvements in the 
6MWT and pain (VAS) parametres in order to achieve a standardised measure of the 
amount of change. An effect size is the size of the relationship between two variables 
and is usually defined as the difference in mean outcomes between a treatment and a
placebo group. Cohen defined d as the difference between the means, M1 - M2, 
divided by the standard deviation of either group (when the variances of the two 
groups are homogeneous). 
	
		–
SD (mean baseline value of the treatment or placebo group)
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This ES calculations are described at http://www.researchconsultation.com/effect-
size-calculation-help.asp , and by Fan and Konold (135). In this thesis, the effect size 
was calculated for each group as well by the formula: 
mean week16 value – mean baseline value
SD (mean baseline value)
Effect sizes are generally defined as small (d = .2), medium (d = .5), and large (d =
.8). 
ETHICAL ASPECTS
Written, informed consent was obtained from all participating patients. They were 
informed that they could withdraw from the study at any time. The Regional 
Committee of Medical Research Ethics of Norway gave ethical consent for the RA, 
AS and PPS studies. The NMD study was approved by the internal ethical committee
at the Sunnaas Rehabilitation Hospital, University of Oslo, based upon the fact that
the almost identical study on patients with postpolio syndrome was approved by the 
Regional Ethical Committee the year before. Furthermore, The Norwegian Social 
Science Services/ Data Inspectorate approved the collection, processing and storage 
of personal information attained in the RA and AS study. 
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SUMMARY OF 
RESULTS
PAPER 1 -RA
THE EFFICACY OF REHABILITATION FOR PATIENTS WITH 
RHEUMATOID ARTHRITIS: COMPARISON BETWEEN A 4-
WEEK REHABILITATION PROGRAMME IN A WARM AND A 
COLD CLIMATE
This study was designed as a randomised, controlled, parallel group trial to compare 
the effects of therapy given in a Mediterranean climate versus in a Norwegian 
climate. The 124 RA patients applying for rehabilitation were randomized to a 
rehabilitation programme either in Norway or in a Mediterranean climate. The 
participants were examined clinically immediately before (week 0) and after (week 
4), as well as three months after (week 16) the rehabilitation period. They also 
answered a mailed questionnaire after six months (week 28). Long-term effect was 
defined as a sustained effect for at least three months. The 28-Joint Disease Activity 
Score (DAS28), the American College of Rheumatology (ACR) response, and 
physical tests were used to measure clinical response.
We found that the baseline DAS28 value 4.45(1.16) was reduced by -0.95 
(1.05) in the Mediterranean climate and the baseline DAS28 value 4.18 (1.17) was 
reduced by -0.37(0.92) in the Norwegian climate at week 16 (p=0.003). An ACR20 
improvement was achieved in 25% of the patients treated in the Mediterranean 
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climate and 15% of those treated in the Norwegian climate. Sustained improvement 
in all ACR core components at week 16 and in patient’s assessment of health status 
at week 28 was found in the patients treated in the Mediterranean climate only. Tests 
of physical function, the Six Minute Walk Test (6MWT) and the Timed Up and Go
(TUG) showed comparable improvements in patients treated in both climates.
In short, we found that RA patients had positive immediate effects on disease 
activity, physical function, and symptoms during a four week rehabilitation 
programme. The effects on disease activity and symptoms were greater and better 
maintained at least three months after rehabilitation in a warm than in a cold climate,
while the effects on physical function were comparable in the patients treated in both 
climates three months after the rehabilitation period.
PAPER 2 -AS
THE EFFICACY OF REHABILITATION FOR PATIENTS WITH 
ANKYLOSING SPONDYLITIS: COMPARISON BETWEEN A 4-
WEEK REHABILITATION PROGRAMME IN A WARM AND A 
COLD CLIMATE
The 107 AS patients in this study were part of the randomised, controlled, parallel 
group trial described for the RA patients. They were randomised to a four week in-
patient rehabilitation programme in Norway or in a Mediterranean country and 
evaluated at the same time points. The ASsessments in Ankylosing Spondylitis 
working group’s Improvement Criteria (ASAS-IC), and tests of spinal mobility and
physical capacity were used to measure treatment response.
In these patients, we calculated the proportions of patients who fulfilled the 
pre-defined improvement criteria at week 16. For the ASAS20 and ASAS40 
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improvement criteria, we found improvement in 50% and 29% of the participants in 
the Mediterranean group and 23% and 10% of the participants in the Norwegian 
group. The proportion of patients who achieved a 20% and 40% improvement in 
Schober’s test was 43% and 29% in the Mediterranean group and 25% and 10% in 
the Norwegian group. In addition, the proportion of patients with 20% and 40% 
improvement in lateral flexion was 91% and 75% in the Mediterranean and 54% and 
39% in the Norwegian group.
This study showed that AS patients had a sustained positive effect of a four 
week rehabilitation programme both in a Mediterranean climate and in a Norwegian 
climate. Nearly all disease variables were still improved both in the Mediterranean 
climate and the Norwegian climate groups at week 16. While the improvements in 
physical capacity were comparable, the improvements in the patient’s assessments of 
health status and spinal mobility measures were greater and better maintained at least 
three months after rehabilitation in a Mediterranean climate.
PAPER 3 -PPS
TREATMENT OF PATIENTS WITH POSTPOLIO SYNDROME IN
WARM CLIMATE
In this study, 88 patients with postpolio syndrome were randomised into three 
groups. One group underwent a four week physiotherapy programme at Tenerife, a 
second group received a similar treatment in Norway, while the participants in the 
third group followed their ordinary health care programme (control group). All 
patients were tested at the start of study, and three and six months later, and the 
patients in the intervention groups were tested after the rehabilitation period as well. 
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The aim of the outcome measures was to cover the three levels of WHO’s defined 
consequences of disease; impairment, disability and handicap, including physical 
tests and several questionnaires.
In short, we found that PPS patients had positive sustained effects on both 
symptoms and physical function three months after a rehabilitation programme in a
warm climate, but on physical function only after a rehabilitation programme in a 
cold climate. Effects on depression measured by Beck’s Depression Inventory were 
seen in both the control and the warm climate group. A summary of the results in the 
chosen outcome measures of this study is given in Table 10, the parametres still 
significantly improved at week 16 are highlighted (136).
Table 10. Summary of results from the PPS and NMD studies in an ICF perspective. 
Sustained improvements three months after the intervention (week 16) are highlighted.
Variables ICF code PPS NM
Body functions and structures wc cc co
ntr
ol
wc co
ntr
ol
Pain
10cm or 100mmVAS (116)
1-6 Likert scale
b280 Sensation of pain
**
**
**
x x
Fatigue
Fatigue Severity Scale (117;118)
b130 Energy and drive 
functions *** ***
Subjective health complaints 
(SHC), (=Ursin Holger 
Inventorium) (119)
Chapter b2 More sensory
functions and pain *** **
Handgrip strength
Grippit Deluxe Hand Dynano-
meter Jamar Limited (120)
b730 Muscle power
*** *** * x x
Lung function
Micro Plus Spirometer (121)
b440 Respiration functions
x x
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Activity
Walking endurance 
Six Minute Walk Test (6MWT) 
(122;123)
b4550 General physical 
endurance and  
d450 Walking
*** ** ***
Fast walking (measured by a 20 
m walking test) (122;123)
b770 Gait pattern functions 
and d450 Walking *** **
Mobility/ balance 
Timed Up and Go (TUG) (124)
d420 Transferring oneself 
and d450 Walking *** * ***
Rivermead Mobility Index (125)
(122)
d410 Changing basic body 
position
Activities of daily life
Sunnaas ADL index (126)
b620 Urinary function 
d455 Moving around 
d510 Washing oneself 
d520 Toileting
d540 Dressing
d550 Eating
d560 Drinking 
d630 Preparing meals
d640 Doing housework and 
d399 Communication, 
unspecified
x x
Participation
Quality of life
Life Satisfaction Scale (127;128)
d750 Informal, social 
relationship, 
d760 Family relationship
d770 Intimate relationship 
d870 Economic self-
sufficiency d859 Work and 
employment
**
Mood
Profile of Mood States (POMS) 
(129)
b152 Emotional functions
b1263 Psychic stability x x x ***
Depression
Beck’s Depression Inventory 
(BDI) (130)
B152 Emotional functions, 
b180 Experience of self and
time functions
*** * x x
Significant improvement from baseline: *=p<=0.05, **=p<=0.01, ***=p<=0.001. wc=warm 
climate, cc=cold climate, x= parametre not used in this study
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PAPER 4 -NMD
PATIENTS WITH NEUROMUSCULAR DISEASES BENEFIT FROM 
TREATMENT IN WARM CLIMATE
The aim of this study was to explore if a four week rehabilitation programme in a 
warm climate influenced health for patients with neuromuscular diseases. We chose 
a RCT with crossover design, thus all the participants were followed through one 
period of intervention and one period of  “life as usual.” Randomisation was 
performed after the first baseline examinations. Long-term effects were defined as 
changes in physical and psychological functions persisting after three months (week 
16) and several scales according to WHO’s classification of functioning were used. 
Primary and secondary outcome measures were defined prior to study start, thus, we 
could improve the statistical conditions, and still cover the large variety of symptoms 
and complaints in these patients.
We found sustained improvements on symptoms, tests of physical function 
and the Profile of Mood States (POMS) three months (week 16) after the
rehabilitation programme in a warm climate. Basic ADL functions (Rivermead 
Mobility Index) remained unchanged, and there was a reduction in the Life 
Satisfaction Scale during the control period. A summary of results in the chosen 
outcome measures of this study is given in Table 10 and the parametres still 
significantly improved at week 16 are highlighted.
This study shows positive long-term effects on the body functions and 
structures, the activity and the participation dimensions of health after a four week 
rehabilitation program in a warm climate for patients with neuromuscular diseases. 
This effect might be due either to the program or to the warm climate or to a
combination of these.
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GENERAL DISCUSSION
METHODOLOGICAL 
CONSIDERATIONS
OVERALL DESIGN OF THE STUDIES
The three studies of this thesis are designed as randomised controlled trials (RCTs). 
The objective of a RCT design is to sort out how one single factor influences the 
results of an intervention. When implementing RCTs in rehabilitation medicine, you 
meet some challenges. Rehabilitation implies a multifactorial approach to a problem, 
or more often, a complexity of problems associated with a disease or a trauma. Thus, 
isolating climate as the only differing factor in the treatment programmes offered in 
warm versus cold climates might be a difficult task. 
Blinding, another important principle in the “gold standard RCT,” has been 
impossible to implement in this study. Both the patients and the therapists have been 
fully aware of being in Norway or in a warmer climate. 
Paul Dieppe has focused on the problems of implementing RCTs in complex 
interventions, such as in a physical therapy trial. Not surprisingly, this concurs with
the methodological challenges of our studies. He pinpoints the difficulty that arises 
when an improvement is gained. The RCT will not allow you to find out how or why 
the intervention has worked—it does not allow us to dissect the effects of, for 
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instance, the therapists and their personalities from the exercises they recommended. 
Thus, the attained improvement may not have helped in an understanding of what is 
going on after all (137).
The NMD study was designed as a crossover RCT. In this design, the 
participants followed both intervention periods, which reduces the inter patient 
variation in the obtained data. The fact that only one of the periods included 
treatment, while the other was a control period only, ascertains the efficacy of 
rehabilitation in warm climate only, which has weakened the impact of this study. 
STANDARDISATION OF TREATMENT?
The intervention given in the studies of this thesis fulfil the definition of 
comprehensive rehabilitation given in the introduction, apart from the fact that the 
occupational therapy might be somewhat scanty and that the self-management 
programme might differ in quality at some of the rehabilitation centres. 
In the postpolio study, the physiotherapists in our study group attempted to 
isolate climate as the only differing factor by standardising the physiotherapy 
programme at each rehabilitation centre before the first patient group arrived. This 
made us able to conclude about a possible difference in efficacy of a physiotherapy 
programme when given in a warm or in a cold climate setting.  
The design of the study of neuromuscular diseases did not include an 
intervention group in Norway, but had a crossover design comparing treatment in a 
warm climate with no extra intervention (control group). This made us able to 
conclude whether the intervention in warmer climate was better than no intervention. 
In the RA and AS study, we focused more on evaluating “the existing” 
treatment than on exploring the climatic influence only. Thus, the physiotherapy 
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programmes were comparable, but not identical. The main difference was the passive 
therapy including balneotherapy given in the Mediterranean climate centres only. A
consequence of this design was that each centre had the opportunity to use their 
specialty in their treatment. This might give a better result for the individual patient, 
but in a scientific view, it weakens the validity of a conclusion about the difference 
in efficacy when a four week rehabilitation programme is given in a warm climate 
versus a cold climate. However, our results might indicate from which of the existing 
treatments the patients benefit most. This might in turn be the most interesting fact to 
know for the patients, their medical therapists, and in a health economic view. 
CONFOUNDING VARIABLES
For the interventions, more than the climatic conditions differed between the 
programmes offered in a cold and a warm climate setting. Daily light exposure 
differs between the centres attended, and this might influence disease activity in RA 
patients according to some studies (92;138;139). Factors that come with the change 
in environment and being far away from home and daily duties might also be of 
importance. Furthermore, the positive psychosocial effects of spending time together 
with other people and participating in a social life might be of importance for the 
total experience of wellbeing. These confounding variables are hard to control for,
and imply that we have to be careful with our conclusions about climatic influence.
INCLUSION AND REPRESENTATIVENESS
To what degree that our results are generalisable might be affected by the different 
inclusion procedures used to gain participants in the three different studies. Hence, it 
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is appropriate to discuss whether the study participants were representative of the 
actual patient population. The participants in the RA and AS study were recruited 
from the applicants to a rehabilitation programme in a Mediterranean country,
administered by the Section for Climate Therapy or from the applicants to the North 
Norway Rehabilitation Centre (RNNK) in Tromsø. Accordingly, these patients are 
likely to be more motivated to participate in a four week rehabilitation programme 
than other patients might be. Many of them were supposed to have earlier experience 
with, and expectations for, the warm climate treatment programme. 
There is an aspect of self-selection in the participants of the NMD study, as 
well. They were recruited by an advertisement in six large newspapers as well as in 
the magazine of the Norwegian association of patients with muscular diseases. In 
addition, information from this study was given to the Norwegian association of 
patients with muscular diseases and to two different departments of neurology that 
treat patients with neuromuscular diseases. Not surprisingly, a large proportion of the 
participants were members of the Norwegian Association of Patients with Muscular
Diseases. This might bias the selection towards the more informed part of this patient 
population, which might have a higher degree of disease acceptance than other 
patients.
In the PPS study, we invited patients that had once been at Sunnaas 
Rehabilitation Hospital (SunRH). Therefore, the patient population was selected 
according to specific criteria from the information available in a hospital journal. A 
“hospital population” of patients might have a more severe manifestation of the 
disease than other patients with the same diagnosis.
The inclusion and exclusion criteria of a study are likely to cause a selection 
bias. Because of practical and economical considerations, all participants should be 
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able to handle primary activities of daily living without assistance. Therefore, the 
persons with severely reduced physical function were not included in any of our 
studies, and our conclusions are not directly generalisable to be valid for these 
patients.
DIAGNOSIS AND VALIDITY
The most important inclusion criterion in all these studies was that the actual 
diagnosis had to be verified by a specialist according to specific diagnostic criteria. 
This was assured by information in hospital journals in the PPS patients, and by 
medical records enclosed in the doctor’s application in the RA, AS and NMD 
patients. In the RA and AS study, we had to exclude some of the study participants 
from the analysis because of uncertainty about the diagnosis based on our own 
medical examination at baseline. This is likely to increase the validity of our results 
in the sense that we have included the patients we intended to.  
DROPOUT RATE AND VALIDITY
A selection of patients prior to study start might affect the generalisability of the 
study result. When the participants drop out during the study period, the selection 
bias might affect the intern validity of the study findings. To evaluate the harm of a
high dropout rate, it is essential to know why the patients dropped out of the study. 
The reasons could indicate whether the patient selection is likely to bias the results or 
not. 
When counting the dropouts of our studies, we find some typical patterns. A
not negligible percentage of the participants withdrew immediately after 
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randomisation. This occurred in both the PPS, RA and AS studies, but not in the 
NMD study that had a crossover design which means that all participants received 
intervention in both a warm climate and a control period. If withdrawal occurs as a 
consequence of disappointment with the randomisation result, a selection bias might 
influence the study results. However, Mouffett et al. asked the patients in their RCT 
about which therapy they would prefer before randomisation, and demonstrated that 
the patient preference did not significantly affect response to treatment (140).
In the RA and AS study, more patients dropped out after randomisation in the 
Norwegian group than in the Mediterranean group, even though we included the 
subjects who were willing to be randomised to both climate groups only. Because 
these persons basically had applied for rehabilitation in a warm climate, the Section 
for Climate Therapy guaranteed rehabilitation in a warm climate the next year for the 
patients who agreed to stay in the study even though they were randomised to 
rehabilitation in Norway. This might have reduced the number of dropouts 
somewhat. 
The reasons for withdrawal after randomisation in the RA and AS patients are 
given in Table x. More subjects specify dissatisfaction with the randomisation result
as their reason for withdrawal after randomisation in the Norwegian than in the 
Mediterranean climate group, but this number of patients is quite small. 
Unfortunately, many of the participants did not give any reason why they chose to 
withdraw from the study, thus we are left to speculate.
The only variables available in the persons who discontinued after randomisation 
were the stratification variables age, sex, the use of disease modifying anti-rheumatic 
drugs (DMARDs) in the RA patients, and the type of articular involvement 
(axial/peripheral) in the AS patients. The last mentioned variables were chosen to 
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reflect the severity of RA/AS. In these variables, the dropouts were comparable to 
the completers in both the RA and the AS part of the study. The reasons for dropout 
after randomisation before intervention in the RA and AS study are given in Table 
11a.
In the PPS study, we had a significantly better baseline values in the control 
group compared to the intervention groups in the mobility and walking tests. This 
bias in physical function might be a result of the fact that more patients dropped out 
Table 11a. The reasons for dropout after randomisation before intervention in the RA 
and AS study, sorted by frequency
Reasons for dropout after randomisation
Number of RA 
patients
Number of AS 
patients
Mediterr
anean
climate
Norway Mediterr
anean
climate
Norway
Practical consideration 1 5 2 7
Dissatisfaction with the randomisation result 1 4 1 3
Acute trauma/ hospitalisation 4 3
Responsibility at home 2 2 2
Elective therapy (drug infusion, surgery) 1 2
Economical reason 2 1
No need for rehabilitation (improved health 
status)
2
Did not meet at the rehabilitation centre 2
Unknown reason 5 9 5 13
Total 12 29 10 28
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from the intervention groups (n=7+8) than from the control group (n=2) (Figure 3-
pps flow chart). Did the drop-outs of the intervention groups have physical function 
lower than the mean? The given reasons for dropout after randomisation do not 
support this theory (Table 11b); nevertheless, there are more factors that could 
influence the obtained baseline data.
Table 11 b The reasons for dropout after randomisation before intervention in 
the PPS study, the known reasons sorted by frequency
Reasons for dropout after 
randomisation
Number of PPS patients
Tenerife Norway Control
Responsibility at home (work, family 
situations)
4 2
Holiday in warm climate 
(Dissatisfaction with the randomisation 
result?)
1 3
Medical reasons 2
Practical reasons (long distance to travel) 2
Economical reasons 1
Unknown reasons 2
Total 7 8 2
The number of dropouts after the initiation of intervention were rather low in all 
of our studies; this is supposed to affect the validity in a positive direction.
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PATIENT EXAMINATIONS AND RELIABILITY
The reliability of a study depends upon which outcome measures you choose to 
measure the patients’ health status, as well as how you perform these measurements 
and tests. The selection of outcome measures in our studies aimed at internationally 
accepted instruments and core sets that had been tested for reliability and validity. 
We aimed to use outcome measures that reflected the actual patients’ problems and 
were responsive to physiotherapy interventions.
The main challenge in our studies was the performance of the physical 
tests and the doctors’ examinations. Ideally, all patient evaluations should have been 
performed by the same investigator. However, when the patients stayed at different 
rehabilitation centres across the world at the same time, we had a logistical problem. 
In the PPS and NMD studies, two physiotherapists managed to do all of the physical 
tests at all treatment centres. In the RA and AS studies, two physiotherapists and one 
nurse did the physical tests, and four physicians did the doctors’ examinations, two in
each climate group. Apart from a few exceptions, each study patient was examined 
by the same physiotherapist, nurse or doctor at all controls.
It has been shown that are wide variations among observers for joint 
counts(132;141). Thus, the inter-rater variation is supposed to reduce the reliability 
of our study results. The fact that each study patient was examined by the same 
investigator at all controls reduces the impact on this variation within group analyses. 
Therefore, the measured improvements within each group might be more reliable 
than the between group comparisons, particularly in the joint count analysis of the 
RA study.
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STATISTICAL ANALYSIS
In all studies of this thesis, we have performed statistical analysis for two group 
comparisons. Since we had four different examination points, we considered whether 
a General Linear Model of Repeated Measures analysis would be a better choice.
This statistical method analyses the variation in a variable in the course of time, and 
whether this course differs between two or more groups. This method is perfect for 
the analysis of growth curves in children, for instance. However, in our studies, we
expect a peak effect immediately after the intervention and not only variation during 
time, thus we ended up with simple two group comparisons after all.
Rehabilitation implies a multifactorial approach to a problem, or more often a 
complexity of problems associated with a disease or a trauma. This complexity of 
both patient problems and types of intervention has resulted in more outcome 
measures in our studies than recommended in a statistical view. In the theory, every 
20th parametre is supposed to show a significant change by chance when the chosen 
level of significance is set to be 0.05. Thus, we considered performing adjustments 
due to multiple testing in our studies. However, the fact that Bonferroni’s correction 
of multiple comparisons presumes independency between the variables tested and the 
tests in our studies were on the same subjects using highly correlated variables, 
Bonferroni’s correction was judged to be too conservative (142).
Even though we had three different groups in the PPS study, we did not use 
the One-way analysis of variance (ANOVA), but two group comparisons only. In the 
NMD study, we selected five primary and four secondary outcome measures prior to 
study start in order to reduce the statistical problem of multiple comparison.
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GENERAL DISCUSSION OF MAIN 
RESULTS
EFFICACY IN THE DIFFERENT PATIENT GROUPS
EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS 
In this study, RA patients had an improved physical function and exercise capacity 
lasting for at least three months after a four week rehabilitation programme both in 
the Mediterranean and Norwegian climates. The changes in physical tests were 
comparable, while improvements in DAS28 score, ESR, physician’s global 
assessment of disease activity and patient’s assessments of health status were greater
in warm than in cold climates. The patient evaluations of health status remained 
improved after three and six months in the patients that were treated in the 
Mediterranean climate only.
Johansson and Sullivan found an immediately better effect of physiotherapy 
in a warm climate compared with outpatient treatment in Sweden (100). Our study 
confirms that there is also a difference in long-term efficacy, measured by the 
DAS28 score, ESR, physician and patient evaluations of disease activity which 
showed greater improvements after therapy in a warm than in a cold climate.
DISEASE ACTIVITY REDUCTION?
Potentially detrimental effects on disease activity have been the focus of earlier 
research of exercise therapy in RA patients. Some earlier studies and two reviews 
agree on the lack of detrimental effects as mentioned in the introduction 
(31;33;38;40). However, do we have any evidence for a reduction in disease activity 
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after an exercise or an in-patient rehabilitation programme in RA patients? This 
might be an interesting matter of discussion. 
In our study, the baseline DAS28 value 4.45(1.16) was reduced by -
1.14(0.80) after the four week physiotherapy programme, and by -0.95 (1.05) at the 
three month check-up (week 16) in the Mediterranean climate group. The 
corresponding values in the Norwegian climate group were 4.18 (1.17), -0.57(0.76) 
and -0.37(0.92). Häkkinen et al. used the DAS28 as a measure of disease activity as 
well. They compared strengthening exercises with range of motion (ROM) and 
stretching exercises performed for 45 minutes twice a week for a two year period 
(40). The mean (SD) DAS28 decreased significantly from 4.4 (1.2) to 2.2 (1.2) in the 
strength exercise group and from 4.9 (1.1) to 2.7 (1.2) in the ROM exercise group 
during a two year training period in their study.  After the two year measurements, all
subjects were instructed to carry out the strength training programme and aerobic 
exercises two to three times a week. At the five year check-up visit, the 
corresponding DAS indices were 2.3 (1.0) in the  strength exercise and 3.0 (1.2) in 
the ROM exercise group (41). This reveals a decrease in disease activity in a long-
term aspect.
Our four week study with three month follow-up had comparable baseline 
DAS28 values at moderate disease activity, but demonstrated a numerical lower 
reduction in this disease activity score. However, the subjects of our study had a 
median disease duration of nine to ten years and the study of Häkkinen et al. 
included only early arthritis patients (disease duration <24 months at inclusion). The 
fact that DMARD therapy was initiated in all patients after the baseline 
measurements is supposed to be a serious confounder with respect to the attained 
DAS28 reduction in their study. However, they demonstrated a significant between 
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group difference between -0.5 and -1.0 for all follow-up controls in favour of the 
strength training group. The maintenance of the attained improvement is supposed to 
be dependent on the subjects’ continuation of exercising during the follow-up time. 
SJC
Van den Ende et al. investigated the benefit of intensive dynamic exercises in 
comparison to range of motion (ROM) and isometric exercises in rheumatoid 
arthritis in 1996. The participants of this RCT had a mean disease duration of 8,4-
11,5 years and unchanged medication during the exercise period. Therefore, they are 
considered to be comparable to the participants in our study. The SJC in the patients 
of the high intensity exercise
programme decreased significantly by -1.7 from 5.2  at the check-up after 12 weeks
with a high intensity exercise programme. Still, the overall conclusion was that the 
disease activity remained unchanged during the exercise period (35).
This was supported  by Minor et al. in a similar study of aerobic versus 
nonaerobic exercise, demonstrating the efficacy of aerobic exercises in physical 
capacity, depression and anxiety, but finding no significant between-group 
differences in flexibility, number of clinically active joints, duration of morning 
stiffness, or grip strength (34). = Minor 1989
In a dance-based aerobic exercise for rheumatoid arthritis study of Pearlman 
et al., analyses of pretest to posttest changes after a 16-week program (twice weekly 
for two hours) indicated no deleterious effects on disease activity. In fact, physician-
assessed articular pain and swelling decreased significantly (143).
Lyngberg et al. focused on disease activity in their crossover study of 18 RA 
patients comparing aerobic conditioning and strength exercises over an eight week 
period. They demonstrated that training of the muscles acting over the swollen joints 
92
resulted in more than a 35% decrease in the number of swollen joints. The 
hemoglobin level increased significantly after the training period, while the 
erythrocyte sedimentation rate, the complement factor C3d, and the number of sore 
joints remained unchanged. Their conclusion was that rheumatoid arthritis activity 
decreased with fewer swollen joints and higher hemoglobin level after training, and 
that RA-patients with some activity are trainable without aggravating the disease, 
even in the chronically swollen joints (144). This is interesting in the context of our 
findings of a persisting reduction in SJC at week 16 of 30% and 40% in the cold and 
warm climate group, respectively. Numerically, it concurs with the 33% decrease of 
the SJC in the 68 joint count status of the Lyngberg study and a 33% reduction in the 
high intensity exercise group of van den Ende et al. as well (35).
ESR
The median, baseline ESR in our study was 20 mm and 17 mm in the warm and cold 
climate group, respectively. We found some small changes at week four, but a
greater ESR reduction in the warm climate group at week 16. A similar ESR 
reduction pattern was seen in the AS patients attending the same study. In the RA 
patients treated in a warm climate, the mean reduction was -8.9 mm which 
constitutes a 45% reduction. Whether this could be an indication of a delayed 
reduction in disease activity might be an object of discussion. 
However, the number of patients affected by diseases that might influence the 
outcome of our study was registered. Significantly more participants experienced
intercurrent diseases during the warm climate intervention than during the cold 
climate intervention, 19% and 6%, respectively. The corresponding values were 10% 
and 8% for the follow-up period (week four to week 16). This is supposed to reflect 
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the higher risk of infectious diseases when visiting a foreign country, and might 
interact with a potential anti-inflammatory effect of a rehabilitation programme in 
warm climate.
Some other studies of exercise therapy have used ESR as an outcome 
measure with varying results. Lyngberg et al. found no significant changes in ESR in 
their eight week study of physical training (144). Neuberger et al. report positive 
effects of 12 weeks of low-impact aerobic exercise on fatigue, aerobic fitness, 
without worsening their arthritis, based upon no significant increases in joint count or 
ESR. Looking closer to the results of this study, they report a significant decrease in 
mean ESR from end of treatment to follow up 15 weeks after completion of the 
exercise programme. This decrease was from 30.0 mm to 16.2 mm, which constitutes 
a 54% reduction from the end of treatment value, which is comparable to the 45% 
reduction in the ESR value in the similar period of the RA patients of our study of 
treatment in a warm climate (29).
In 2007, Neuberger et al. present a new and more comprehensive RCT of 220 
RA patients participating in either a class exercise, home exercise or a control group, 
measuring disease activity variables as total joint count, ESR and CRP. These 
variables appeared to be strikingly stable during the 12 weeks of exercise, supporting 
the conclusion on no significant increases in measures of disease activity (145), and 
perhaps answering the question about reduction in disease activity as well. 
THE WARM CLIMATE EFFECT
The DAS28 improvement attained in the subjects of our study of treatment in a
Mediterranean climate was clinically significant after three months according to the 
EULAR response criteria’s definition of moderate improvement: > 0.6 when 
moderate disease activity ( 3.2-5.1) at baseline (146). The intervention given to this 
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group of patients consisted of more than just exercise therapy. To what extent do the 
“sunny, warm, dry and stable climatic conditions” play a role in the differences in 
attained improvements in this disease activity score? A regression analysis could 
have made us more capable of ruling out climate as an explanatory variable for the 
differences in improvements between the warm and cold climate intervention. The 
study setting might be too complex to be able to ascertain this as a cause and effect  
relationship; however, there is some rationale for the fact that factors in the 
Mediterranean climate, such as more UV-radiation (147;148) and daylight time 
(138;139), may affect disease activity in RA patients. This might be supported by the 
study of Drosos et al. demonstrating a clinical, radiologic, and serologic more severe 
disease of RA patients in Britain versus Greece (88), concluding that both genetic 
and environmental factors may be responsible for the differences in disease 
expression.
Hashkes demonstrated an immediate ACR20 improvement in 57% of the RA 
patients of his uncontrolled study of climatic therapy, concluding that the “short term 
effect of climatic therapy are not less than for most new medications” (104). In our 
study, an immediate ACR20 improvement was achieved in 38% of the patients in the 
Mediterranean group and 21% in the Norwegian group. This proportion of 
responders is lower than shown in Hashkes’ study. However, more patients with low 
levels of SJC and TJC at baseline were included in our study, and a high proportion 
of patients with zero values made improvements according to the ACR criterion 
difficult to obtain. Shorter disease duration and more active disease were associated 
with a greater response in RA patients according to Hashkes. The patients of our 
study had median disease duration of 9-10 years, and the baseline DAS28 score 
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indicated a moderate disease activity (146). Thus, ACR improvement might not be 
the most appropriate response criterion in our study. 
THE EFFECTIVENESS OF A SUPPLEMENTARY INTERVENTION
Reviewing the effectiveness of comprehensive rehabilitation programs, Uhlig et al. 
found only a modest effect on measured outcomes after comprehensive rehabilitation 
in rheumatologic conditions (52). They pinpoint the fact that the patients with access 
to qualified care are supposed to also have undergone drug therapy earlier, and often 
in conjunction with a rehabilitation programme. Thus, comprehensive rehabilitation 
is supposed to be supplementary to at least regular medical care. This poses a 
difficulty in generating significant or clinically important changes in outcome 
measures, because improvements caused by pharmacological interventions may 
exceed rehabilitative effects (52). Thus, the moderate number of patients attaining an 
ACR20 improvement in our study might be better understood in this context.
REHABILIATION IN WARM CLIMATE REVIEWED
Recently, a systematic review collecting the evidence for the efficacy of 
comprehensive rehabilitation in a warm climate of patients with a wide variety of 
rheumatic diseases has been presented online (149). Our study was one of the six 
studies that met the inclusion criteria and the only one assessed to be of moderate 
quality of evidence according to the GRADE approach (150). For patients with 
rheumatoid arthritis, moderate evidence was found for reduction of disease activity, 
pain, fatigue, and global disease impact. The evidence was also moderate that 
comprehensive rehabilitation in a warm climate did not improve fitness or reduce 
activity limitation beyond levels reached by rehabilitation in Scandinavia. 
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The main goal of rehabilitation in RA patients is to improve the patients’ 
functional capacity and prevent further deterioration (99). Consequently, the obtained 
positive effects at the functional level are of importance.
EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS
ASAS20 RESPONSE
Seventy-nine percent of the AS patients treated in a warm climate compared to 44% 
of the AS patients treated in a cold climate were immediate responders according to 
the ASAS20 response definition in our study. In 2002, Hashkes evaluated the 
efficacy of a comparable four week in-patient rehabilitation programme in Israel, 
demonstrating an immediate ASAS20 response in 60% of the AS patients. However,  
this number is supposed to be underestimated since they did not measure more than 
three of the four separate ASAS items defined, and thus their criteria for 
improvement became more stringent (107). The number of responders after 
rehabilitation in a warm climate was similar to that of anti-	


found for AS patients (151).
However, the obtained effects of the rehabilitation programme decline with 
time in contrast to the continuous anti-	
This concurs with the 
uncontrolled study of Lubrano et al., evaluating 52 active AS patients consecutively 
admitted to a rehabilitation inpatient clinic in Italy, demonstrating improvement by
the ASAS response criteria (152). The number of ASAS20 responders in their study 
was 89% at the end of the rehabilitation, 60% 6 weeks, and 33% 12 weeks after the 
end of therapy. In our study, 50% and 23% had persisting ASAS20 improvement 16 
weeks after the initiation of the four week rehabilitation programme in warm and 
cold climate, respectively.
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SUSTAINED IMPROVEMENT OF SPINAL MOBILITY
The baseline Schober at 3.3cm improved to 4.0cm after intervention and 3.8cm 16 
weeks after initiation of intervention in a warm climate. The corresponding values 
were from 3.2cm to 3.3cm and 3.4cm in a cold climate. Different exercise 
programmes for AS patients have shown improvements similar to the warm climate 
intervention. Viitanen et al. demonstrated a baseline Schober at 3.3cm, improved to 
3.6cm immediately after the three to four week in-patient rehabilitation, but reduced 
to 3.2cm at the 15 months follow-up (60). The patients had been encouraged to 
continue exercises at home, but had not been offered any group or follow-up regime. 
In the study of Altan et al., Schober improved from 3.19cm to 3.65cm after three
weeks of intensive treatment, including daily balneotherapy and home exercises. 
This intervention was followed by a 30-min home exercise program for six months, 
improving the mean Schober value to 4.12cm in the intervention group (153). This 
pinpoints the value of continuation of an exercise programme subsequent to an 
intensive physiotherapy programme. Analay et al. compared home exercises to 
supervised group exercises, finding that group exercises improve movement in the 
spine more than home exercises. In the intervention group of their study, a baseline 
Schober at 4.38cm was improved to 5.26 after six weeks of intervention (58). The 
participants of this study were aged 18 to 55 years and the criteria for inclusion might 
have resulted in a selection of the less affected patients with a baseline Schober close 
to normal. However, none of these studies show improvements above a 10mm level;
this concurs with Viitanen et al.’s clinical assessment of spinal mobility 
measurements in ankylosing spondylitis, evaluating the Schober test to be both a 
valid and reliable measurement, but not very sensitive to change (154;155).
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However, the obtained improvements in spinal mobility seem to be more 
stable than the ASAS improvements in our study. Lateral lumbar flexion is a 
responsive measure judged by a high standardised response mean (SRM) (0.84), and 
has been recommended among the spinal mobility measures (113). The number of 
patients having 20%/ 40% improvement in lateral flexion remained high even three 
months after the four week rehabilitation programme (week 16): 91/75 in the 
Mediterranean group and 54/39 in the Norway group. Thus, our study supports the 
poor-quality evidence for long-term effects on improved mobility following an 
inpatient physiotherapy programme for AS patients (59;60). Warm and stable 
climatic conditions may enhance rheumatic patients’ capacity to perform physical 
exercise (105); this might explain why the improvements in our study were greater
when the rehabilitation was performed in a Mediterranean climate.
SPA-EXERCISE THERAPY
The patient’s assessments of symptoms like pain, global health, morning stiffness 
and fatigue showed a remarkable reduction immediately after the intervention in our 
study. The improvements persisted for 16 weeks after intervention in a cold climate 
and for 28 weeks after a rehabilitation programme in a warm climate. This concurs 
with the study of van Tubergen et al. demonstrating a spa-exercise therapy to 
improve pain and overall well-being more than a weekly group exercises programme 
alone (61), and that the beneficial effects may last for at least 40 weeks. The 
standardized spa exercise therapy of three weeks' duration consisted of group 
physical therapy, walking, correction therapy (lying supine on a bed), hydrotherapy, 
sports and visits to either the Gasteiner Heilstollen in Austria or to the sauna in The 
Netherlands in their study. This combination of spa and exercise therapy is 
comparable to the complexity of the intervention in warm climate given in our study. 
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The fact that there is a huge variation in the content and duration of in-patient 
programmes described in literature poses a methodological problem, as types of 
programs vary enormously, and many confounders are difficult to address.
PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS
According to Lubrano et al., rehabilitation was superior to anti- therapy for 
improvements in anthropometric measures (156). Yurtkuran et al. conducted an 
RCT comparing spa therapy to non-steroidal anti-inflammatory drug (NSAID) 
therapy and a combination of both (157). It was found that spa therapy was more 
effective in relieving symptoms and improving spine mobility than NSAIDs alone, 
with the effect lasting up to six months. Thus, physiotherapy and physical exercise 
and/or spa therapy may be a substantial supplement to medical treatment in order to 
improve mobility AS patients.
Consensus has been obtained for the ASAS/EULAR recommendations that 
non-pharmacological and pharmacological treatments are complementary and that 
both are of value in the initial and continuing treatment of patients with AS (53).
REHABILIATION IN WARM CLIMATE REVIEWED
The systematic review summarising the evidence of the efficacy of comprehensive 
rehabilitation in a warm climate of patients with a wide variety of rheumatic diseases 
found low evidence for reduction of disease activity, pain, joint range of motion, 
activity limitation, and global disease impact among patients with ankylosing
spondylitis (149). The level of evidence may have been increased if the paper about 
the AS patients in our study had been published prior to this systematic review.
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EFFICACY IN PATIENTS WITH POSTPOLIO SYNDROME
Our study indicates significant health effects in PPS patients after a four week 
rehabilitation programme both in Norway and in Tenerife. The attained 
improvements were greater and longer lasting when treatment was given in a warm 
climate.
In 2006, the European Federation of Neurological Societies (EFNS) 
developed an evidence-based guideline for the diagnosis and management of 
postpolio syndrome. Our study was reported as high class (Class I) evidence for the 
efficacy of treatment both in a warm and in a cold climate. No other studies of  in-
patient rehabilitation programmes were referred (158).
In 2009, Davidson et al. reported prolonged benefits for physical, 
psychological and functional outcomes after comprehensive rehabilitation in PPS 
patients (159). The 27 patients who completed this uncontrolled study were 
comparable to the patients in our study concerning mean age, mean age of polio 
onset and PPS symptom onset, but in contrast to our study, more men than women 
were included. In this rehabilitation study, significant improvements were recorded 
for exercise endurance, depression and levels of fatigue, but there was no significant 
change at six months for muscle strength or anxiety. These patients were treated in 
London and were thus comparable to the cold climate group of patients in our study. 
In comparison, we found improvements in endurance, but also handgrip strength and 
mobility in both climate groups. The improvements in fatigue, depression and pain 
were sustained in the warm climate group only.
Evidence based recommendations of physiotherapy, physical activity and 
muscle training in PPS patients are given in a recent review (2010) about the 
management of postpolio syndrome by Gonzalez et al.  (160). Even though an 
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intensive rehabilitation programme is not mentioned as a recommendation, the main 
components of a rehabilitation programme given in our study are recommended. 
Aquatic exercise being an important part of the programme (161). Furthermore, it is 
claimed that the training programmes should be carefully customised and planned by 
physiotherapists to avoid both overuse and disuse, and the level of physical activity 
modified to decrease pain (160), which is supposed to be easier to realise in an in-
patient rehabilitation context.
EFFICACY IN PATIENTS WITH NEUROMUSCULAR DISEASES 
Our study showed positive effects on different dimensions of health with at least 
three months’ duration following a four week rehabilitation program in a warm 
climate for patients with neuromuscular diseases. Statistical significant 
improvements were revealed in the primary outcome measure for pain (VAS scale), 
endurance (six minute walking test), fatigue (Fatigue Severity Scale), and mobility 
(Timed up and go).  
Dahl et al. evaluate the effect of a four week rehabilitation programme for 
patients with hereditary, congenital neuromuscular diseases similar to those included 
in our study (109;110). This trial had a RCT design with 20 patients being treated in 
a warm climate and 20 patients in a cold climate. Apart from this study, no 
comparable study of any intensive physiotherapy programmes for patients with 
hereditary, congenital neuromuscular diseases was found in medical databases. But a 
systematic review of Cup et al. in 2007 concludes with level II evidence (likely to be 
effective) for strengthening exercises in combination with aerobic exercises for 
patients with muscle disorders, and that most studies reported the absence of adverse 
effects (162).
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The improvement in exercise capacity demonstrated in our study was an 
increase of 54 m during six minutes walking persisting three months after treatment 
in a warm climate. Dahl et al. demonstrated an improvement of 60m (from 343(87)m
to 403(104)m) in the Mediterranean climate and 53m (from 384(117)m to 
437(130)m) in the Norwegian climate group. In this study, no significant difference 
was found between the two climate groups. 
In 2009, Albresch et al. summarized the current knowledge regarding the 
effect of exercise on individuals with NMDs concluding that there is inadequate 
evidence from randomized controlled trials with sufficient sample size to make 
recommendations (163). In a “rehabilitation in practice” article of 2010, Gita M 
Ramdharry focuses on weakness as a primary impairment of neuromuscular diseases. 
She concludes that research to date has helped to dispel the old practice of exercise 
avoidance in neuromuscular conditions and that exercise trials are starting to answer 
some questions found in muscle disease, poliomyelitis and hereditary neuropathy 
(16). Both Albresch and Ramdharry agree that results from the aerobic studies 
performed almost uniformly show that individuals who are mildly affected by the 
disease or who are early on in the course of their disease demonstrate short-term 
cardiopulmonary improvements that are similar to those seen in persons without
NMDs, but the level of training and kind of training depends on the type, stage, and
severity of the disease (16;163).
The baselineVAS pain score was 25 in our study and 26 for both climate 
groups in the study of Dahl et al. (109;110). A statistically significant improvement 
of nine (22) was revealed in our study. It might be a matter of discussion whether this
improvement is of clinical importance. Dahl et al. revealed an immediate relief from 
103
pain after intervention in the warm climate only, but this change did not persist three
months after intervention. 
When exercise can improve cardiovascular fitness, it may help to reduce 
experienced fatigue (16). A statistically significant reduction in fatigue measured by 
the Fatigue Severity Scale (FSS) was found to persist even three months after the 
intervention in our study. A median baseline score at 4.7(4.0-5.5) was reduced by 0.5 
(-0.2-1.6). Dahl et al. demonstrated an immediate improvement from mean 4.8(1.5) 
to 3.9 (1.5) in FSS in the warm climate group of his study, but this improvement did 
not persist after three months. Robert Miller has reviewed recent studies of fatigue in 
common neurological conditions, discussing therapeutic interventions (164). He 
states that fatigue is one of the most common causes of disability in patients with 
neurological disease. Peripheral and central fatigue mechanisms often coexist. 
Several groups have demonstrated benefits from therapeutic exercise, although the
mechanisms of action are poorly understood and may not be specific (164).
In conclusion, the improvements attained at the activity level in our study are 
found to be probable and seem to be rather persistent. Thus, our randomised, 
controlled trial supports an effect of an intensive physiotherapy programme 
maintained for at least three months. The improvements in symptoms like pain and 
fatigue are essential for the group of patients with NMDs. According to Dahl et al., 
the improvements in these symptoms might be more transient and may differ 
according to which climate the physiotherapy programme was given. The study of 
Dahl et al. is considered to be comparable to our study including similar diagnosis 
and outcome measures. It is striking how similar the baseline values and attained 
improvements are in these studies. This is considered to support our findings, and 
introduces the aspect of different climate settings not ascertained in our study.
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6MWT IMPROVEMENTS ACROSS DIAGNOSIS
The Six Minute Walk Test (6MWT) measures how many metres you manage to walk 
in six minutes and it is widely used in different patient groups. The performance of 
this test depends on multiple health factors and is supposed to reflect functional 
capacity (165). Walking few metres might indicate a deconditioned state, or
immobility in the lower limbs according to pain or paresis. Especially in older 
people, the 6MWD appears to provide a measure of overall mobility and physical 
functioning rather than a specific measure of cardiovascular fitness (166). This 
physical test was an important outcome measure of all studies included in this thesis. 
An overview of the mean responses obtained in this parametre in the different 
diagnosis at week 16 are presented in Table 12; effect sizes above medium level are 
coloured. This may form the basis for some interesting comparisons. 
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The normal values of this test may be computed according to the reference equations 
presented by Enright and Sherrill in 1998 (167). They administered the standardized 
Six Minute Walk Test to 290 healthy adults, aged 40 to 80 years, and measured 
median distance walked to be 576 m for men and 494 m for women. Thus, the RA
Table 12.  An overview of the 
sustained mean responses in the 
Six Minute Walk Test (6MWT), metre,
at week 16 in the different diagnosis, 
with corresponding effect sizes  
n
Changes from 
baseline
Baseline 
values
Week 16 p value Effect 
Size (ES)
Rheumatoid arthritis
Mediterranean group 72 550(86) 58(52) 0.001 0.67
Norwegian group 52 547(85) 64(53) 0.001 0.75
Diff between the groups 0.559 0.07
Ankylosing spondylitis
Mediterranean group 65 559 (84) 68 (65) 0.001 0.81
Norwegian group 42 566 (99) 59 (54) 0.001 0.60
Diff between the groups 0.470 0.11
Postpolio syndrome
Mediterranean group 27 347(119) 84(45) 0.001 0.71
Norwegian group 23 316(149) 40(62) 0.003 0.27
Control group 26 414(120) -4(49) 0.536 0.03
Diff between MC-Nor 0.005 0.37
Diff between MC-Control <0.001 0.74
Diff between Nor-Control 0.003 0.30
Neuromuscular diseases
Mediterranean group 44 387(85) 54(65) 0.001 0.64
Control group 44 387(85) 2(38) 0.62 0.02
Diff between the groups <0.01 0.61
Baseline values are shown as mean (SD), and changes from baseline are shown as mean 
	!"	#$#	&$+>!"	@Z!"	
Effect sizes are generally defined as small (d =0 .2), medium (d = 0.5), and large (d = 0.8), all 
medium or large effects are coloured. Diff=difference.
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and AS patients included in our study had a baseline value comparable to healthy 
subjects, while the baseline values were moderately reduced in the subjects with 
neurological diseases. The strikingly large SD of the PPS patients’ baseline values 
indicate a greater variation in their walking speed than among the other patient 
groups. 
Technical aids like crutches and manual wheelchairs in the performance of 
this test were allowed. None of the participants in the RA and AS study used 
wheelchairs.  In the postpolio study, 11 patients used manual wheelchairs and 17 
used powered wheelchairs, some permanently and others occasionally. The 
corresponding number was 12 manual and 18 powered wheelchairs in the 
neuromuscular study. Those who were completely dependent on a powered 
wheelchair were excluded from the test, while those who were dependent on a 
manual wheelchair performed the test with their wheelchair. 
In the original postpolio article, the mean value was given for week 16 (three 
months’ control) while the mean difference from baseline has been given in the other 
studies. The between group comparisons presented in the original postpolio study 
compare the mean values at week 16, independent of the baseline value. In hindsight,
it would have probably been a better idea to compare the mean difference from the 
baseline as has been done in the other studies.  This would have given a more correct 
presentation of the real differences in improvement between the groups as presented 
in Tables 2, 3 and 4 in the 3rd paper of this thesis. 
Effect sizes are generally defined as small (d = .2), medium (d = .5), and large 
(d = .8). It is striking that all included patients showed a sustained improvement of 
medium or large effect size after treatment in a Mediterranean climate, no matter the 
diagnosis. While the rheumatic patients had a similar improvement after treatment in 
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a Norwegian climate and in a Mediterranean climate, the size of effect was small 
after treatment in a Norwegian climate for the PPS patients. The control groups 
showed no significant improvements at all.
Studies using the Six Minute Walk Test (6MWT) as an outcome measure 
differ in their definition of minimal clinically significant difference (MCSD) from 30 
and 56 metres (168;169). Paul L. Enright reports that a 12-40% mean improvement
from baseline values has been published for various interventions (170). It is 
important to bear in mind that these studies involve patients with pulmonary 
diseases, which might limit the transfer value of the results. However, the definition 
of MCSD corresponds well to the fact that all attained improvements calculated to 
have medium or large effect size (above 0.5) in our studies, have an improvement of 
54 metres or greater.
VAS PAIN IMPROVEMENTS ACROSS DIAGNOSES
Pain is described as a common complaint in all four patient groups included in this 
thesis. We have used the 100mm VAS scale for a subjective rating of the intensity of 
pain in all patient groups. The baseline values and change from baseline 16 weeks 
after initiation of intervention (three month control) are presented in Table 13, effect 
sizes above a medium level are coloured. This may form the basis for some 
interesting comparisons. 
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The ankylosing spondylitis patients had the highest and the neuromuscular patients 
had the lowest baseline pain scores. We found persistent improvements at week 16 in 
Table 13
An overview of the sustained mean 
responses in VAS pain (0-100) at 
week 16 in the different diagnoses,
with corresponding effect sizes
n
Changes from baseline
Baseline 
values
Week 16 p value Effect 
Size 
(ES)
Rheumatoid arthritis
Mediterranean group 72 42 (22) -16 (24) 0.001 0.73
Norwegian group 52 44 (22) -4 (22) 0.197 0.18
Diff between the groups 0.005 0.55
Ankylosing Spondylitis
Mediterranean group 62 53 (21) -20 (32) 0.001 0.95
Norwegian group 42 49 (19) -13 (21) 0.001 0.68
Diff between the groups 0.180 0.33
Postpolio syndrome
Mediterranean group 29 42 (22) -14 (24) 0.003 0.64
Norwegian group 26 43 (24) 1 (14) 0.969 0.04
Control group 29 40 (19) -7 (21) 0.063 0.37
Diff between MC-Nor 0.006 0.68
Diff between MC-Control 0.241 0.32
Diff between Nor-Control 0.112 0.33
Neuromuscular diseases
Mediterranean group 51 25 (25) -9 (22)* <0.01 0.36
Control group 51 25 (25) 0 (15) 0.90 <0.01
Diff between the groups 0.03 0.36
Baseline values are shown as mean (SD), and changes from baseline are shown as mean difference 
from baseline (SD). *Changed to negative after consultation with Petra A. Nordby, who analysed the 
original data. Diff= difference. ES= Effect size= +>!"	@Z!"	#
sizes are generally defined as small (d =0 .2), medium (d = 0.5), and large (d = 0.8), all medium or 
large effects are coloured. 
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all patient groups after rehabilitation in a Mediterranean climate. Effect sizes are 
generally defined as small (d = .2), medium (d = .5), and large (d = .8). The measures 
effect size (ES) was relatively high (0.64-0.95), except for the patients with 
neuromuscular diseases having ES below 0,5. Only the ankylosing spondylitis 
patients had statistically significant reduced pain 16 weeks after rehabilitation in 
Norway, and in the rheumatoid arthritis and postpolio patients, we found a 
statistically significant difference in efficacy between the Mediterranean climate and 
the Norwegian climate groups. For the neuromuscular patients, there was a 
significant difference between the intervention and control group at week 16; this 
was not the case for the patients with postpolio syndrome, which might question how 
valuable the within-patient improvements in this patient group really are. However, it 
is important to bear in mind the seasonal variation in Norway, affecting all groups 
being tested during spring time.  
Whether the sustained improvements in VAS pain are of clinical significance 
might be a matter of discussion. In a study on acute pain in emergency medicine 
(171), the minimal clinically significant difference (MCSD) in the VAS pain score 
was determined to be 12 mm (95%CI: 9mm to 15mm). This study concludes that the 
MCSD in the VAS pain score did not differ according to the severity of pain being 
experienced. Another study of patients with both traumatic and non-traumatic pain 
found the MCSD in the VAS pain score to be 9 mm (95%CI: 6mm to 13mm), and 
that the MCSD did not differ significantly according to age, sex and cause of pain
(172). This corresponds well to the fact that all attained improvements in our studies 
which are calculated to have a medium or large effect size (above 0.5), have an 
improvement greater than 12 mm.
110
POTENTIAL MECHANISMS OF 
IMPROVEMENT
According to Hafström and Hallengren (105), the benefits of a physiotherapy 
programme could be due partly to the climate and partly to the change in
environment, as well as to the intense coordinated physiotherapy. The most afflicted 
patients have been shown to improve most after a physiotherapy programme in a 
warm climate (100;101). Johansson og Sullivan analysed the correlation between  
background variables and the efficacy of physiotherapy in a warm climate (100).
How the patients reported their symptoms were more highly correlated to disease 
activity measures than to personality traits, measured by Edwards’ personality
inventory. Furthermore, they demonstrated that emotional or psychosocial problems 
at baseline had a negative influence on the outcome of this intervention. Thus, we 
have some signs that might support a mechanism of improvement at an objective 
level.
It is important to bear in mind that there are differences in the nature of the 
neurological and the rheumatic diseases included in this thesis. The neuromuscular 
diseases are slowly progressive; the postpolio syndrome might be better 
characterised as a sequelae state, even though there is a component of progression in 
this disease as well. The fluctuating state of disease activity is an important aspect of 
the rheumatic diagnosis studied.
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ANTI-INFLAMMATORY EFFECT?
DO THE ESR CHANGES REFLECT A DISEASE ACTIVITY 
REDUCTION IN THE RA AND AS STUDY?
The acute phase reactants are not increased in all AS patients, and the value of an 
acute phase reactant to measure disease activity is uncertain (173). The baseline ESR 
in the AS patients of our study was on the upper border of normality. We found some
small changes at week four, but a greater ESR reduction in the Mediterranean 
climate at week 16. A similar ESR reduction pattern was seen in the RA attending 
the same study. Are these reductions of clinical importance? In the AS patients 
treated in a warm climate, the mean reduction was -8.3mm from a baseline median 
value at 17.0mm, which constitutes a 49% reduction. In the RA patients, we found a 
45% reduction at -8.9mm from a median baseline at 20.0mm. Whether this could be 
an indication of a delayed reduction in disease activity might be an object of 
discussion.
SUN EXPOSURE INDUCES RAPID IMMUNOLOGICAL CHANGES 
IN SKIN AND PERIPHERAL BLOOD IN PSORIASIS PATIENTS
An induction of rapid immunological changes in skin and peripheral blood in 
psoriasis patients after sun exposure has been demonstrated by Søyland and Heier et 
al.  This very interesting finding is described in a submitted article (174) and is 
included in the doctoral thesis of Ingvild Heier (175). This study group examined 
immunological parametres in 20 psoriasis patients who underwent heliotherapy for 
16 days on Gran Canaria. In addition to local immunmodulatory effects in both 
lesional and non-lesional skin, they revealed immunmodulatory changes in 
peripheral blood. The number of cutaneous lymphocyte antigen (CLA)+T cells was 
significantly decreased in peripheral blood after only one day in the sun and 
remained reduced at day 16. At day 16, phytohaemagglutinin (PHA) -stimulated 
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peripheral blood mononuclear cells (PBMCs) released significantly reduced levels of 
the following pro-inflammatory cytokines:  interferon (IFN)-	
#-17,
tumour necrosis factor (TNF)-$	
#-10 compared to baseline levels.
On this basis, they conclude that sun treatment had a systemic effect. A systemic 
effect of sun treatment in psoriasis patients opens for similar immunological changes
in other persons with other diseases.
IMMUNOLOGICAL FACTORS AND CHRONIC INFLAMMATION 
IN PPS PATIENTS 
Increasing interest in recent years has been devoted to the immunological process 
underlying postpolio syndrome. Concentrations of several cytokines, mainly those 
with proinflammatory actions (e.g., interferon- and tumour necrosis factor [TNF]), 
are high in the CSF of PPS patients (176). These findings probably reflect chronic 
inflammation in the spinal cord parenchyma, with potential damage to motor 
neurons. Potential causes of this chronic inflammation include a late aberrant 
immune response to the original infection, a late autoimmune complication of the 
original infection, and an immune response secondary to ongoing neurodegeneration 
caused by other factors. If the neurodegeneration in postpolio syndrome is an
ongoing process caused by chronic inflammation, treatment of the disorder with 
drugs that modify the immune response should be possible. A randomised controlled 
trial of intravenous immunoglobulin in PPS patients has shown efficacy in muscle 
strength, vitality and physical activity in the treatment group; however, many of the 
parametres did not differ from the placebo group (177). Notwithstanding, this is an 
interesting finding in the context of potential anti-inflammatory effects of climate 
therapy.
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UV-RADIATION 
High doses of ultraviolet radiation may induce immunosuppression (147;148;178).
Ullrich et al. have discussed the role of immunosuppression in phototherapy and
have argued that the pathology of diseases such as vitiligo, alopecia and lichen 
planus are thought to involve immune mechanisms; thus, the beneficial effect of 
PUVA may be due to immunosuppression. Furthermore, phototherapy may then be 
beneficial in the treatment of autoimmune disease and allergic reactions (147).
Weichenthal and Schwarz have continued to study the mechanism of  UV- radiation 
in phototherapy and conclude that many of the effects certainly are mediated via 
induction of apoptotic cell death, and that another major mechanism is the induction 
of immunosuppression (148).
In 1991, Urbach discussed the increase in biologically effective ultraviolet 
radiation due to the decline of stratospheric ozone concentration over the Northern 
Hemisphere in the past 20 years. He predicts  the effects on human health to consist 
of increases in nonmelanoma skin cancer and malignant melanoma of the skin, 
possible alterations of immune response, and development of lens cataracts  (178).
DAILY LIGHT EXPOSURE
Cutolo et al. studied the circadian rhythms of serum melatonin, cortisol, and 

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daily light exposure might influence the circadian rhythms of these hormones and 
cytokines. Reduced daily light exposure as observed in northern Europe (Estonia), at 
least during the winter, might explain the higher and more prolonged serum 
melatonin concentrations that were observed in northern RA patients, as well as 
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some epidemiological features versus southern Europe patients (138). The fact that 
the production of proinflammatory cytokine related to melatonin stimulation 
might in turn increase the disease activity in these RA patients. In another paper, 
Cutolo et al. present a northern and southern Europe comparison, stating that 
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
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patients from a northern European country with reduced daily light exposure than in 
matched controls or in rheumatoid patients from a southern European country (139).
Thus, the potential explanation of some differences in the epidemiological features in 
northern versus southern European patients might be the difference in daily light 
exposure. In addition, the efficacy of a rehabilitation programme might be influenced 
by the geographic position of the rehabilitation centre, especially in patients with an 
inflammatory disease. 
VITAMIN D PRODUCTION
Turner et al. studied the serum 25-hydroxyvitamin D, opioid intake and Short Form-
36 Health Status Questionnaire in 267 chronic pain patients at admission to a pain 
rehabilitation center. They demonstrated vitamin D inadequacy in 26% of the
patients using opioids, needing a higher mean morphine equivalent dose for a longer 
time period than the vitamin D adequate group. Opioid users with inadequate vitamin 
D levels reported worse physical functioning and health perception than opioid users 
with adequate levels. This might  provide the basis for the assertion that vitamin D 
inadequacy may represent an under-recognized source of nociception and impaired 
neuromuscular functioning among patients with chronic pain (179).
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According to Shinchuk and Holicks’ review about Vitamin D and 
rehabilitation, Vitamin D inadequacy is pandemic among rehabilitation patients in 
both inpatient and outpatient settings. Vitamin D deficiency causes osteopenia, 
precipitates and exacerbates osteoporosis, causes the painful bone disease 
osteomalacia, and worsens proximal muscle strength and postural sway. Vitamin D 
deficiency and osteomalacia should be considered in the differential diagnosis of 
patients with musculoskeletal pain, fibromyalgia, chronic fatigue syndrome, or 
myositis. Vitamin D inadequacy can be prevented by sensible sun exposure and 
adequate dietary intake with supplementation (180).
BALNEOTHERAPY EFFECT?
It is not known whether the minerals of mineral water penetrate the body surface, but 
they are known to cause a so-called spa or mineral water reaction (181). The mineral 
water reaction includes tiredness and fatigue especially after 5–8 baths with an 
associated rise in the leukocyte count and erythrocyte sedimentation rate even within 
the normal range. The mineral water reaction passes away after 5–10 baths, and the 
optimal “taking the waters” is a total of 15–22 baths taken daily (82).
SPINAL MOBILITY
The obtained improvements in spinal mobility seem to be more stable than the ASAS 
improvements in the AS patients. This might indicate that an intensive rehabilitation 
programme could postpone the stiffening process in the columna of AS patients. 
According to Lubrano et al. , rehabilitation was superior to anti- 	
&

improvements in anthropometric measures (156). Thus, physiotherapy and physical 
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exercise may be a substantial supplement to medical treatment in order to improve 
mobility AS patients. Warm and stable climatic conditions may enhance rheumatic 
patients’ capacity to perform physical exercise (105), and this might explain why the 
improvements were greater when the rehabilitation was performed in a
Mediterranean climate. 
QUALITY OF LIFE AND “RESPONSE SHIFT” 
Most of the study patients appreciated that the rehabilitation was given for a group of 
patients with similar diagnosis. Many of the participants experience social isolation 
at home due to their physical limitations. To meet other persons with the same types 
of diagnoses can be valuable in terms of handling the stress that may derive from loss 
of abilities regarded as valuable (182). The quality of life measured by the 
questionnaire, Life Satisfaction Scale, in the neuromuscular study did not show any 
long-term effect. This is in contrast to the impression based on the participants’ 
statements. A potential explanation can be that this questionnaire focused on
satisfaction with life in general and everyday life and might not be sensitive to 
possible changes in aspects such as coping and self-esteem.  Scott and Garrood have 
noted that quality of life instruments are only moderately sensitive to changes 
induced by rehabilitation therapy (183).
The notion “response shift” describes how an individual may change self 
understanding either through internal standards, values and/or quality of life (184).
This is not unlikely to be an effect of a treatment in warm climate in a group of 
people with a similar diagnosis and everyday problems. Thus, the aspect of life 
quality might both have a positive, but also a negative effect in these kinds of studies.
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In the postpolio study, we used the Beck’s Depression Inventory (BDI, 0-63) 
(130), which measures depression as a phenomena more than quality of life. 55% of 
the participants reported cases of depression, i.e. a score above nine on the BDI at 
baseline, reflecting that depression is rather common among patients with postpolio 
syndrome. Furthermore, we found a significant reduction in mean BDI three months 
after intervention. In hindsight, we might have found a better instrument to measure 
life satisfaction in a population with presumably normal mental health.
WHICH ASPECTS OF THE COMPREHENSIVE 
REHABILITATION ARE THE MOST APPRECIATED 
AND WHICH ARE WELL DOCUMENTED?
The “National clinical guideline for management and treatment in adults with 
rheumatoid arthritis” is prepared by The National Collaborating Centre for Chronic 
Conditions (NCC-CC) funded to produce guidelines for the National Institute for 
Health and Clinical Excellence (NICE). This evidence-based European treatment 
guideline is presented by the Best Practice database and defines the components of 
physiotherapy interventions to include:
 Exercise therapy:  on land and in water (hydrotherapy/aquatic physiotherapy) 
and includes aerobic activities, flexibility and muscle-strengthening exercises, 
core stability exercise, balance rehabilitation, and promotion of lifestyle 
physical activity.
 Patient education and self-management:  joint protection strategies, energy
conservation/fatigue management, sleep hygiene training, management of 
flare, pain relief strategies, relaxation training, exercise and physical activity 
recommendations.
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 Thermotherapy:  hot/cold packs, paraffin/wax baths and infrared.
 Electrotherapy: Transcutaneous Electrical Nerve Stimulation (TENS), 
Ultrasound, Pulsed Electromagnetic Energy (PEME), Interferential therapy 
(IFT) and Laser.
 Occupational therapy: Provision and education of use of assistive devices:  
walking aids, splints, orthoses, and insoles.
 Manual therapy:  includes mobilisation, manipulation, myofascial release, 
trigger point therapy, acupuncture and massage.
These components of physiotherapy interventions might be appropriate in the 
rehabilitation of more patients than simply those with rheumatoid arthritis. Apart 
from the fact that electrotherapy was mainly given in the rheumatic patients treated 
in warm climate, and occupational therapy was offered to a wider extent in the 
rehabilitation of the neurological patients, these main components were included in 
the physiotherapy programme given in our studies.
Van den Berg et al. have done a survey of a random sample of people with 
rheumatoid arthritis to investigate their attitude towards physical activity or exercise.
Supervised group exercise and unsupervised individual physical activity were 
reported as the favourite activities. Furthermore, more people preferred being 
physically active under expert supervision than without supervision and preferred 
water-based over land-based activities. The most frequently-mentioned barriers were 
lack of energy, presence of pain, lack of motivation, lack of information, and fear of 
joint damage (185).
In our study of rehabilitation in postpolio patients, the participants rated 
which part of the programme they appreciated most. Individual physiotherapy was 
rated highest both in the Tenerife group and in the Norway group. In the Tenerife 
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group, the climate was rated second, followed by water-based exercises and social 
activities. In the Norway group, water-based exercises were rated second followed by 
social activities and self-training.
The patients with neuromuscular diseases included in our study report that it 
is not only the structured training programme or the warm climate that is important,
but the combination of these components. Having time to recover after 
training/treatment was also reported to be important. 
SUMMARY OF EVIDENCE STATEMENTS FOR THE 
COMPONENTS OF PHYSIOTHERAPY INTERVENTIONS
The evidence for the efficacy of each component of a comprehensive rehabilitation 
programme are most thoroughly studied in RA patients (186). The efficacy may 
differ in other patient groups. However, the efficacy of a physiotherapy modality is, 
to some extent, supposed to be consistent.
EXERCISE THERAPY –HIGH EVIDENCE
In general, exercise provokes a favourable response in terms of physical and 
psychological benefits in RA patients (31;37;46;145;187-189). Aerobic (dynamic) 
exercise programmes improve the components of health-related fitness, enhance 
psychological status, reduce pain and fatigue and have a positive effect on functional 
capacity without exacerbating disease activity or accelerating joint damage 
(31;37;42;145). Specific exercise aimed at enhancing joint range of motion (joint 
flexibility) or muscle strength (resistance training) results in some specific 
improvements (37;187). The majority of evidence comes from patients with chronic, 
stable RA in functional class I/III (31;37).
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HYDROTHERAPY – ADDITIONAL FEELING OF WELL-BEING
Exercise in water provides similar physical benefits to exercise on land but may have 
additional and important psychological effects (which positively impact on 
concordance) (187;189).
BALNEOTHERAPY
Yurtkuran et al. conducted an RCT in 2005 comparing spa therapy to non-steroidal 
anti-inflammatory drug (NSAID) therapy and a combination of both in AS patients
(37). It was found that spa therapy was more effective in relieving symptoms and 
improving spine mobility than NSAIDs alone, with the effect lasting up to six
months (157)
In the 2008 update of Verhagen et al.’s Cocrane review about balneotherapy 
in RA patients, they conclude that an answer about the apparent effectiveness of 
balneotherapy cannot be provided at this moment. Seven trials were now included; 
however, the inconclusiveness was caused by methodological flaws (83).
In 2009, Falagas et al. did a systematic review of balneotherapy in various 
diseases. They found balneotherapy to improve pain in patients with rheumatological 
diseases and chronic low back pain in comparison to the control group in 17 (68%) 
of the 25 RCTs examined. This beneficial effect lasted for 10 days to one year in the 
studies reviewed. They concluded that there is a possibility that balneotherapy is 
associated with clinical improvement in rheumatological diseases mainly such as
osteoarthritis, fibromyalgia, ankylosing spondylitis, rheumatoid arthritis and chronic 
low back pain. However, existing research is not sufficiently strong to draw firm 
conclusions (84).
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GROUP SUPERVISION
Adoption of regular physical activity and exercise strategies is more successful if 
personalised contact with a health professional occurs in which the benefits and 
barriers to exercise are discussed and there is opportunity for group contact (145).
PATIENT EDUCATION AND SELF-MANAGEMENT
Educational interventions are provided to support patients to cope with the 
consequences of the disease. In RA, two systematic reviews on educational 
interventions consistently conclude that only interventions that involved behavioural 
change techniques provided a small but significant short-term effect on pain,
functional disability and psychological status, while those that offered counselling or 
“information only” showed no additional benefit (190;191).
THERMOTHERAPY
Vivian Robinson et al. performed a Cochrane review in 2002, evaluating the 
effectiveness of different thermotherapy applications on objective and subjective 
measures of disease activity in patients with RA (192). Seven RCTs were included, 
showing no significant effect on objective measures of disease activity including 
joint swelling, pain, medication intake, range of motion (ROM), grip strength, hand 
function compared to a control (no treatment) or active therapy. However, no 
harmful effects of thermotherapy were reported. On this basis, they concluded that 
superficial moist heat and cryotherapy can be used as palliative therapy. Paraffin wax 
baths combined with exercises can be recommended for beneficial short-term effects 
for arthritic hands. However, these conclusions are limited by methodological 
considerations such as the poor quality of trials.
122
ELECTROTHERAPY
The data for clear benefits of the use of electrophysical agents in the management of 
RA is lacking. The present data set highlights conflicting results in mainly poor 
quality studies in which multiple interventions and outcomes confuse synthesis; 
therefore, little confidence can be attached to the findings. However, some agents, 
e.g. TENS suggest that short-term symptomatic relief may occur (193). Ultrasound 
applied in water to the dorsal and palmar aspects of the hand has shown increased 
grip strength as compared with placebo (194).  There is 'silver' level evidence that 
low level laser therapy for up to four weeks in people with rheumatoid arthritis does 
decrease pain and morning stiffness. It does not appear, however, to have long-
lasting effects (195).
OCCUPATIONAL THERAPY
Occupational therapy for rheumatoid arthritis is reviewed by Steultjens et al. in 2004 
(196). Thirty-eight out of 58 identified occupational therapy studies fulfilled all 
inclusion criteria. The results of the best evidence synthesis shows that there is strong 
evidence for the efficacy of “instruction on joint protection” and that limited 
evidence exists for comprehensive occupational therapy in improving functional 
ability. Indicative findings for evidence that “provision of splints” decreases pain are 
found. Thus, there is evidence that occupational therapy has a positive effect on 
functional ability in patients with rheumatoid arthritis.
MANUAL THERAPY
Massage, a form of manual therapy, is the systematic manipulation of soft tissues of 
the body for pain reduction or other therapeutic purposes (197). To date, there is no 
controlled clinical trial on the effectiveness of massage in patients with RA or AS, 
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whereas a review on its safety concludes that adverse advents with the use of classic 
massage are rare (198).
Finally, although the use of complementary and alternative treatments is 
popular in patients with RA and AS, there are very few systematic reviews and RCTs 
in the complementary medicine area (199). In order to facilitate evidence-based 
practice in rheumatology, more research will be needed to guide clinicians’ decisions 
in using complementary and alternative treatments for managing RA and AS.
The evidence of the different components of a comprehensive rehabilitation
programme differs. Uhlig et al. have reviewed the effectiveness of comprehensive 
rehabilitation programmes, concluding that when effects on the various outcome 
measures are demonstrated, improvements can only with difficulty be attributed to a 
specific component of a comprehensive program. Thus, the overall performance of 
comprehensive rehabilitation programs, not the individual components, should be 
evaluated (52).
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CONCLUSIONS
To ease the burden of symptoms by improving self-performance and independence  
is the main objective of rehabilitation, according to Kesselring (200). Compensation 
of functional deficits, adaptation and reconditioning, together with management of 
symptoms, impairment, emotional coping and self-estimation, are all important long-
term objectives. Although rehabilitation may not always have a direct influence on 
the progression of a disease, this form of intervention improves personal activities 
and participation in social activities, thereby improving quality of life.
Our study supports that a multidisiplinary in-patient rehabilitation programme 
of four weeks duration improves different aspects of health in both RA and AS 
patients. Physical exercise therapy increases physical capacity for at least three 
months, no matter the climatic setting. Disease activity in RA is marginally reduced 
in a cold climate, and moderately reduced in a warm climate rehabilitation setting for 
at least three months. Columnal mobility was still improved in 91% and 54% of the 
AS patients three months after intervention in warm and cold climate settings, 
respectively (LatFlex20). The improvements in patients’ health assessments of pain, 
morning stiffness, physical function, disease activity and fatigue lasted six months in 
both RA and AS patients after rehabilitation in a warm climate, for three months in 
AS patients and only immediately after  rehabilitation in a cold climate for RA 
patients. This demonstrates only a short-term ease of the burden of symptoms after a 
cold climate compared to a warm climate rehabilitation programme.
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For the PPS patients, we revealed positive, sustained effects on physical 
function three months after a rehabilitation programme, no matter which climate 
setting. However, a persisting ease of the burden of symptoms appeared after 
rehabilitation in a warm climate only. An effect on depression was seen after the 
warm climate intervention as well as in the control patients during spring time.
The patients with neuromuscular diseases had sustained improvements on 
symptoms, tests of physical function and the Profile of Mood States (POMS) three 
months after a rehabilitation programme in a warm climate. These effects are 
compared to a control period without any intervention, thus we are not able to sort 
out which effect might be due to the warm climate, the programme, or the 
combination of these.
If I may be capable of generalizing on the basis of the different patients 
studied in this thesis, it seems that consistency in rehabilitation focusing on physical 
exercise improves physical capacity, no matter which diagnosis or climatic setting. 
Moreover, rehabilitation in a warm climate has shown to be superior when it comes 
to easing the burden of symptoms like pain and fatigue. This finding concurs with the 
studies indicating that symptoms like pain and stiffness are reduced in a stable 
climate with low humidity, and the demonstration that low temperature and low 
atmospheric pressure increase the risk of joint pain in rheumatic patients, and even in 
arthritic rats. The effects of weather conditions are supposed to be general, however, 
it is likely that climatic influence affects stiff and aching bodies more than the less 
weather sensitive symptoms. The persistent improved columnal mobility of almost 
all AS patients support that a warm, dry and stable climate might pose a better basis 
for the efficacy of mobility exercises. The improvements found in “moods state” and 
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depression among the NMD and PPS patients in the warm climate setting might be a 
consequence of improved personal activities and participation in social activities as 
stated by Kesselring as an effect of comprehensive rehabilitation.
The efficacy of phototherapy in psoriatic patients have been claimed to be 
mediated by an anti-inflammatory effect of UV-radiation for decades. The 
immunmodulatory changes in peripheral blood of psoriatic patients recently 
demonstrated in the study of Søyland and Heier et al. support this anti-inflammatory 
effect. The reduction of both T-cells and level of pro-inflammatory cytokines support 
the theory that being in a warm and sunny climate has a systemic effect. A systemic 
effect in psoriasis patients allows for similar immunological changes in other 
autoinflammatory diseases. This concurs to the moderate reduction of disease 
activity demonstrated in our RA patients treated in a warm climate. The differences 
in the clinical, radiologic, and serologic expression of rheumatoid arthritis (RA) in 
Greek and British patients demonstrated by Drosos et al. support that there might be 
both genetic and environmental factors influencing the disease expression, and the 
higher RA prevalence among Pakistanis living in England than in Pakistan supports 
the impact of environmental factors on the causation of RA.
However, the focus of this thesis was not why, but if there was a difference in 
efficacy when rehabilitation was performed in a warm climate or in a cold climate. 
We have no causational evidence of which factors are responsible for the 
demonstrated differences in effect in our studies. The combination of rehabilitation 
given in beneficial climatic surroundings has shown to be effective. Since 
rehabilitation implies a multifactorial approach to a problem, or more often a 
complexity of problems associated with a disease, each potential mechanism of 
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action is not supposed to give a thorough explanation of the improvements attained; 
however, they may still pose a rationale for the comprehension of an improvement 
above placebo level.
FUTURE STUDIES
RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
Recently, a systematic review collecting the evidence for the efficacy of 
comprehensive rehabilitation in a warm climate of patients with a wide variety of 
rheumatic diseases has been presented online (149). This review concludes that well-
designed studies to validate and improve the low-to-moderate evidence found for the 
efficacy of comprehensive rehabilitation in a warm climate among patients with 
inflammatory rheumatic disease are greatly needed. In order to ascertain the effects 
of the comprehensive rehabilitation from the effects of the change of climate, one 
could design a RCT comparing a four week stay in warm climate with and without 
intervention.
POSTPOLIO SYNDROME
Even though the efficacy of physiotherapy and regular, physical exercise in PPS 
patients has become clearer, the long-term effects (years) are not documented and 
deserve prospective studies. More studies of comprehensive, in-patient rehabilitation 
programmes are needed.
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NEUROMUSCULAR DISEASES 
There is a need for randomised, controlled trials of strengthening and aerobic
exercises versus no intervention, with a long-term follow-up. Studies of a
comprehensive, in-patient rehabilitation programme for NMD patients have not been 
reported in scientific literature. To ascertain the climatic influence on the efficacy of 
an in-patient rehabilitation programme, there is a need for a randomised, controlled 
trial comparing in-patient rehabilitation in warm and cold climate, in addition to a 
control group with no intervention. 
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ERRATA
The following changes have been made in the text after submission to the doctoral 
committee:
Title page (lines 12 and 13): “Department of Rheumatology “ is replaced by 
“Department of Rheumatology, Dermatology, and Infectious diseases, Division of 
Specialised Medicine and Surgery”
Title page (line 15): “Department of Research” is removed
Title page (line 17): “Institute of Clinical Medicine” is inserted
Title page (line 18): “Norway “ is inserted
Title page (line 25): The logos of the two involved hospitals are inserted
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ABSTRACT  
Objective: To investigate the sustained effect of a rehabilitation programme for patients with 
ankylosing spondylitis (AS), and to compare the effect of this intervention given in a 
Mediterranean versus a Norwegian climate. 
Methods: 107 AS patients applying for rehabilitation were randomised to a 4-week in-patient 
rehabilitation programme in Norway or in a Mediterranean country. The participants were 
evaluated clinically before and after the rehabilitation period (week 0 and 4) and in week 16. 
The ASsessments in Ankylosing Spondylitis working group’s Improvement Criteria (ASAS-
IC), and tests of spinal mobility and physical capacity were used to measure treatment 
response. 
Results: At week 16, nearly all disease variables were still improved in both patient groups 
(p<0.027). While the improvements in physical capacity were comparable, the improvements 
in patients’ health assessments and spinal mobility were larger after rehabilitation in a 
Mediterranean country. Sustained improvement according to the ASAS20, Schober20% and 
lateral flexion20% was found in 50%, 43% and 91% of the patients in the Mediterranean 
group versus 23%, 25% and 54% of those in the Norwegian group (p=0.006, NS, p<0.001, 
respectively).  
Conclusion: This study shows that AS patients benefit from a 4-week rehabilitation 
programme in a Norwegian climate, but even more from a similar programme in a 
Mediterranean climate. 
 
Key Words 
ankylosing spondylitis     climate     rehabilitation     physical therapy modalities     treatment 
outcome     randomized controlled trials      
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INTRODUCTION 
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that affects the axial 
skeleton, causing characteristic inflammatory back pain, stiffness, and often peripheral 
arthritis. The prevalence of AS is between 0.1% and 1.4% in Europe (1-3). 
Physiotherapy and supervised exercise are widely accepted as part of the non-
pharmacologic treatment of patients with AS. However, the awareness of published evidence 
on physiotherapy in AS is unsatisfactory (4;5). A recent updated Cochrane review 
summarising the available scientific evidence on the effectiveness of physiotherapy in the 
management of AS concludes that an individual home-based or supervised exercise program 
is better than no intervention; that supervised group physiotherapy is better than home 
exercises; and that combined inpatient spa-exercise therapy followed by group physiotherapy 
is better than group physiotherapy alone (6). 
AS patients report variation in health status according to season and weather 
conditions (7). High doses of ultraviolet radiation may induce immunosuppression (8-10). 
Differences in daily light exposure influence the circadian rhythms of serum melatonin, 
cortisol, tumour necrosis factor {alpha} (TNF{alpha}), and interleukin 6 (IL6), and thus the 
disease activity, in patients with rheumatoid arthritis (11). Melatonin and TNF{alpha} 
(proinflammatory) were significantly higher in rheumatoid patients from a north European 
country with reduced daily light exposure than in matched controls or in rheumatoid patients 
from a south Europe country (12). Low temperature and low atmospheric pressure increase 
the risk of joint pain in rheumatic patients (13) and intensify pain in arthritic rats (14). An 
increase in pain and rigidity were associated both with decreased temperature and increased 
relative humidity in the arthritis sufferers of Aikman’s study (15). According to Patberg and 
Rasker’s review, RA variables are positively correlated with the humidity of the microclimate 
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at the patient's skin, and the classic opinion, "Cold and wet is bad, warm and dry is good for 
RA patients," seems to be true only as far as humidity is concerned (16). 
However, climatic factors might have an additional effect for AS patients participating 
in a rehabilitation programme. No previous controlled study has evaluated the efficacy of 
physiotherapy in warm compared to cold climate for AS patients. However, climatic factors 
have been shown to influence RA patients participating in the same study (17). Some 
uncontrolled studies have reported sustained improvements in self-reported health status after 
3 to 6 months (18-21). Hashkes found 60% responders to climatic therapy using the ASAS 
criteria for improvement (IC) (22), but this study did not include any follow up. 
The current study was conducted to compare the sustained effect of a 4-week 
rehabilitation programme for AS patients in a Mediterranean and a Norwegian climate, using 
the ASAS international working group’s core sets for physical therapy (PT) interventions (5), 
the ASAS-IC (23), and objective tests of physical capacity.  
 
 
MATERIALS AND METHODS 
Eligibility 
The 107 AS patients were recruited from the applicants to a rehabilitation programme in a 
Mediterranean country, administered by the Section for Climate Therapy at Oslo University 
Hospital, Rikshospitalet or from the applicants to the North Norway Rehabilitation Centre 
(RNNK) in Tromsø. The main inclusion criteria were a diagnosis of ankylosing spondylitis 
(AS) (verified by a rheumatologist), a documented need for rehabilitation, age below 70 
years, and reduced physical functioning, but ability to handle primary activities of daily living 
(P-ADL) without assistance. Eligible patients should not have attended a similar rehabilitation 
programme within the last 9-12 months before the intervention. Patients with concomitant 
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diseases that might influence the effect of the rehabilitation programme were excluded: 
unstable heart, lung or endocrinologic diseases, apoplexia cerebri, cancer, mental sufferings 
and any kind of abuse problem, in particular. The inclusion of patients was according to the 
doctor’s application and enclosed medical records. 
 
Study design 
The study was a randomised, controlled, parallel group trial. All eligible patients were invited 
to participate. Those accepting the invitation were randomly assigned to a 4-week 
rehabilitation programme in Norway (North Norway Rehabilitation Centre (RNNK) in 
Tromsø or Skogli Rehabilitation Centre AS in Lillehammer), or a similar treatment in a 
Mediterranean country (Institute Igalo in Montenegro or Balcova Thermal Therapy Centre in 
Izmir, Turkey). Randomisation was done by a statistician with the Splus language for data 
analysis, and was stratified according to sex and type of articular involvement 
(axial/peripheral). The study period lasted from March 2003 until June 2004. 
 The participants were examined immediately before (week 0) and after (week 
4) the intervention period. Three months later (week 16), all participants were re-examined at 
the Department of Rheumatology at Oslo University Hospital, Rikshospitalet or at the 
University Hospital of North Norway (UNN), Tromsø. They answered a questionnaire at 
week 0, 4, 16, and 28 as well.  
 
Intervention 
The participants followed the regular rehabilitation programmes at all centres. The main 
components of the therapy offered were individualised physiotherapy with exercises, group 
exercises, passive therapy, relaxation, and patient education.  
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Active physiotherapy. Individualised physiotherapy was given once daily: on a couch, in the 
fitness department using specially constructed equipments, or in the pool. Group training 
(eight to 15 patients) was given twice daily: in the gym and in a temperature-controlled 
swimming pool. During a week the patients in the Mediterranean group had 15-17 obligatory 
sessions of active physiotherapy lasting 20-45 minutes, and the patients in the Norwegian 
group had 15-16 sessions of 30-60 minutes duration. The exercise therapy aimed at increasing 
endurance, mobility, and strength. While the Norwegian programme included more endurance 
training, the Mediterranean programme had more focus on mobility. At all treatment centres 
the patients were given the opportunity to attend additional, voluntary, physical activities.  
Passive therapy. This therapy comprised thermotherapy, massage, and electrotherapy. 
At the Mediterranean centres (thermo-) mineral water was used for balneotherapy in the 
swimming pools, bubble baths, and underwater massage. Two passive treatments of 10-15 
min a day were usually given to each patient.  At the Norwegian centres, patients received 
passive therapy merely when this was found indicated by the physiotherapist.  
The programme included a 30-45 min supervised relaxation session  two to four times 
a week at Lillehammer, Tromsø, and Balcova. At Institute Igalo activities such as yoga and tai 
chi were offered.  
Patient education. Disease-specific lectures about AS were given at all four centres 
focusing on diet, physical activity, self efficacy, coping techniques, and advice related to 
general health.  
Treatment with disease modifying anti rheumatic drugs was kept constant during the 
intervention and follow up. However, disease related adjustments were allowed. 
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Daylight and climate 
The study period in the warm climate was in May-June 2003 at Institute Igalo in Montenegro 
and September-October 2003 at Balcova Thermal Therapy Center in Izmir, Turkey, both 
located by the Mediterranean Sea. Mean daylight time was 14 h 59 min in Igalo and 11 h 51 
min in Balcova, computed using National Mapping Division's sunrisenset program, version 
2.2. The morning temperature in Igalo ranged from 15.6°C to 30.4°C, mean 24.4°C, and in 
Balcova from 15.0°C to 26.0°C, mean 20.1°C, measured at 8.00/ 7.30am at the Therapy 
Centre. The mean number of days with precipitation above 1.0mm during each 4-week 
rehabilitation period was 2 days in Igalo and 1 day in Balcova. 
The study period in Norway lasted from March to May and September to December 
2003. The patients living in the northern parts of Norway received their rehabilitation 
programme at RNNK in Tromsø, which is located on the Northern Norway coastline, while 
the patients living in the southern parts received their rehabilitation programme at Skogli in 
Lillehammer, which is located in the inland area. Mean daylight time was 12 h 46 min in 
Lillehammer and 15 h 41 min in Tromsø. The morning temperature in Lillehammer ranged 
from -9.3°C to11.8°C, mean 1.7°C and in Tromsø from -6.0°C to 14.9°C, mean 3.0°C 
measured at 7am at the Norwegian Meteorological Institutes. The mean number of days with 
precipitation above 1.0mm during each 4-week rehabilitation period was 7.5 days in 
Lillehammer and 12.0 days in Tromsø.  
 
Outcome Measures  
The patients were assessed for lumbar spinal mobility by the original Schober test: the 
increase with forward flexion of a 10 cm segment with the inferior mark at the level of the 
posterior superior iliac spines (24), and lateral lumbar flexion: the difference between the 
fingertips-to-floor distance in the upright position and at maximum lateral flexion (25). The 
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medical examinations included chest expansion: the difference in the chest circumference 
between full expiration and full inspiration at the 4th intercostal space (26) and erythrocyte 
sedimentation rate (ESR, mm). Exercise capacity was measured by the 6-Minute Walk Test 
(6MWT) (27), and physical capacity was measured by the Timed Up and Go (TUG) (28). The 
total TUG distance was 20 metres, this walking distance and time were measured to calculate 
walking pace. The same assessor performed the medical examinations on the same patient 
throughout the whole study period.  
The patients assessed their own health status by: patient’s global assessment of disease 
activity (VAS 0-10 cm), fatigue (VAS 0-10 cm), Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) (29;30), and Bath Ankylosing Spondylitis Functional Index 
(BASFI) (31;32).  
The ASsessments in Ankylosing Spondylitis working group’s Improvement Criteria 
(ASAS-IC) were used to measure treatment response. An ASAS20 improvement is >20% 
relative improvement and absolute improvement of >1 unit (on a scale of 0-10) in 3 or more 
of the following 4 domains: patient’s global assessment, patient’s perception of pain (question 
2 of the BASDAI), inflammation (mean of question 5 and 6 of the BASDAI), and function 
(BASFI), with no worsening by >20% and >1 unit in the remaining domain (23). ASAS40 
improvement was defined as attaining a >40% relative improvement and an absolute 
improvement of >2 units in 3 or more of the 4 domains, with no deterioration from baseline in 
the remaining domain (33). 
 The response at week 16 was chosen as a main outcome to evaluate sustained effect. 
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Ethics 
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Inspectorate approved the study, and written, informed consent was obtained from all 
participating patients. 
 
Statistics  
Sample size was calculated with the Sample power programme. For patient's assessment of 
pain (VAS; 0-10 cm), 80% power, a minimum clinically significant difference (MCSD) at 0.9 
and a SD at 2.2, we needed 100 participants in each climate group to detect a difference 
between the two treatment groups. Statistical analyses were undertaken with the SPSS version 
13.0.  
Continual data is presented as mean and SD or median and 25th, 75th centiles according 
to whether the observations show normal distribution. To compare two groups we used the 
Pearson Chi-Square Test, or Fisher’s Exact Test when appropriate, for categorical variables, 
independent Samples T-Test for continuous variables with normal distribution, and Mann 
Whitney U-Test for continuous variables without normal distribution.  
The clinical response is given as the mean difference from baseline with corresponding 
standard deviation (SD). Paired Samples T-Test and Independent Samples T-Test were used 
for within group and between groups analysis, respectively. The chosen level of significance 
is probability (p) values < 0.05. 
Since Bonferroni correction for multiple comparisons presumes independency 
between the variables tested and the tests in this study were on the same subjects using highly 
correlated variables, Bonferroni correction was judged to be too conservative (34).  
 
 
Rehabilitation and climate for AS patients 12 
RESULTS 
Patient disposition 
Totally 325 eligible AS patients were invited to participate (figure 1). From these, 154 
patients were randomised for treatment in a Mediterranean country, n=77 or in Norway, n=77, 
and 107 patients were analysed as completers, n=65 in a Mediterranean country (40 in Turkey 
and 25 in Montenegro) and n=42 in Norway (13 in Tromsø and 29 in Lillehammer).  
As many as 171 persons declined to participate in the study, additionally 10 patients 
randomised to the Mediterranean group and 28 patients randomised to the Norwegian group 
withdrew their consent after randomisation. Only 3 (1+2) patients were lost to follow up, and 
6 (1+5) patients did not meet the Modified New York Criteria for Ankylosing Spondylitis 
(1984) at the first medical examination and were thus excluded from the analysis  (35).  
 The known reasons for withdrawal after randomisation before treatment were practical 
considerations, n=9, dissatisfaction with the randomisation result, n=4, acute trauma/ 
hospitalisation, n=3, responsibility at home, n=2, or no need for rehabilitation (improved 
health status), n=2. The reasons for withdrawal were comparable whether randomised to 
rehabilitation in Mediterranean climate or in Norway. Eighteen patients withdrew without 
giving us any reason. 
There was no significant difference between the participants, n=107 (65+42) and the 
non-participants, n= 218 (171+10+1+1+28+2+5) of this study with regard to age (data not 
shown), but the proportion of men was higher among the non-participants (69% versus 57%, 
p=0.029).  
The patients who discontinued after randomisation, n=47 (10+1+1+28+2+5), were 
comparable to the completers, n=107 (65+42) regarding age, sex, and type of articular 
involvement (axial/peripheral) (data not shown). A higher number of patients completed the 
study among those randomised to the Mediterranean group, n=65, than those randomised to 
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the Norwegian group, n=42, (p <0.001), but the completers of the two groups did not differ in 
regard to age, sex, and type of articular involvement (axial/peripheral) (data not shown).   
 
Patient baseline characteristics 
The demographic and disease characteristics were comparable in the 65 patients treated in the 
Mediterranean climate [42% women, mean age 48 (range 28-70) years] and the 42 patients 
treated in the Norwegian climate [45% women, mean age 51 (range 30-62) years] (table I). 
The number of patients using DMARDs or prednisolone at baseline was lower in the 
Mediterranean than in the Norwegian group (p=0.007 and p=0.011 respectively). Still, the 
baseline values of all outcome measures were comparable (table II and III). 
 
Efficacy 
Clinical response was expressed as mean difference from baseline at 4, 16, and 28 weeks after 
initiation of the 4-week rehabilitation programme. Changes in the patient’s assessments of 
health status are presented in table II, and the spinal mobility, ESR, and tests of physical 
capacity in table III.  
At week 16 all examined variables, except chest expansion and ESR, improved 
significantly among patients in both study groups (p<0.027). The improvements at week 16 
were larger for patients treated in Mediterranean countries than for those treated in Norway 
for all examined variables except for the patient’s global assessment, chest expansion, and the 
tests of physical capacity (p<0.049).   
After 28 weeks all patient’s assessments of health status (patient’s global, spinal pain, 
morning stiffness, BASFI, BASDAI, and fatigue) were still significantly improved in the 
Mediterranean group (p<0.001), but not in the Norwegian group.  
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At week 16, the proportion of patients who met the ASAS20 and ASAS40 
improvement criteria was 50% and 29% in the Mediterranean group and 23% and 10% in the 
Norwegian group (p=0.006 and p=0.022, respectively), (figure 2). The proportion of patients 
who achieved a 20% and 40% improvement in Schober’s test was 43% and 29% in the 
Mediterranean group and 25% and 10% in the Norwegian group (NS and p =0.025, 
respectively) (figure 3A). The proportion of patients with 20% and 40% improvement in 
lateral flexion was 91% and 75% in the Mediterranean  and 54% and 39% in the Norwegian 
group (p<0.001) (figure 3B).  
 
Medication 
Thirty-one (48%) of the 65 Mediterranean group patients and four (10%) of the 42 Norwegian 
group patients had ceased or reduced their use of analgesics during the 4-week rehabilitation 
period (p<0.001). Seven patients (11%) had initiated or increased their use of analgesics 16 
weeks after initiation of intervention in the Mediterranean group, compared with no patients 
in the Norwegian group (p=0.041). It was no statistical difference in the number of patients 
that initiated/increased or ceased/reduced NSAIDs, DMARDs, biological drugs and 
prednisolone between the two groups within the study period (data not shown).  
 
 
DISCUSSION 
This study ascertains the effect of a 4-week rehabilitation programme for AS patients 
performed either in a Mediterranean or in a Norwegian climate. Close to all patient’s 
assessments of health status, spinal mobility measures, and tests of physical capacity 
improved significantly 3 months after completion of the programme (week 16) in both climate 
settings. The improvements in the patient’s assessments of health status and spinal mobility 
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measures were larger when the rehabilitation was performed in a Mediterranean country 
rather than in Norway, while the tests of physical capacity showed comparable improvements 
in both climate settings. 
The proportion of ASAS20/ASAS40 responders at 16 weeks after the rehabilitation 
programme was 50%/29% in the Mediterranean group and 23%/10% in the Norwegian group. 
The immediate (week 4) efficacy in the Mediterranean group (79% ASAS20 responders) was 
similar to that of anti-TNFα therapy previously found for AS patients (36).   
The obtained effects of the rehabilitation programme decline with time in contrast to 
the continuous anti-TNFα therapy. This concurs with the uncontrolled study of Lubrano et al., 
being the first to evaluate the effectiveness of a 3-week intensive rehabilitation programme by 
the ASAS response criteria (37). It is not known whether repeated rehabilitation periods could 
give an additive efficacy in AS patients. 
 Brandt et al. have suggested to include spinal mobility and acute phase reactants to the 
original four domains ASAS-IC, which are a composition of patients’ health assessments 
(33). Schober’s test and thoracolumbar lateral flexion have proved to be among the most valid 
measures of spinal mobility, shown as significant correlations with radiological sum scores 
(38). 
The participants of our study had both restricted anterior (Schober’s test) and lateral 
lumbar flexion as well as chest expansion at baseline when compared to normal values (24-
26). The mean improvements in the Schober’s test of this study span from 0.1 to 0.7 cm, 
which are comparable to other studies of different exercise programmes for AS patients 
(39;40). Pile et al. have calculated the mean inter-observer variation to be 0.7 cm and the 
mean intra-observer variation to be 0.6 cm for the modified Schober’s test (41). The high 
degree of variation between each measure in individual patients makes it difficult to define 
the observed improvement to be of any clinical significance. According to Viitanen et al., the 
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Schober’s test is both a valid and reliable measurement, but not very sensitive to change 
(38;42). When using measures insensitive to change, Felson et al. recommend to define 
change on an individual basis, focusing on enumerating which patients improve in a trial, 
rather than on the mean level of improvement (43). Thus, the fact that the number of patients 
achieving 20%/40% improvement in Schober was 43/29 in the Mediterranean group and 
25/10 in the Norway group might be more illustrative than the mean change for the efficacy 
16 weeks after initiation of intervention in this study. 
Lateral lumbar flexion is a responsive measure judged by a high standardised response 
mean (SRM) (0.84), and has been recommended among the spinal mobility measures (33). 
The number of patients having 20%/ 40% improvement in lateral flexion remained high at 
week 16: 91/75 in the Mediterranean group and 54/39 in the Norway group.  
The obtained improvements in spinal mobility seem to be more stable than the ASAS 
improvements in this study. This might indicate that an intensive rehabilitation programme 
could postpone the stiffening process in the columna of AS patients. According to Lubrano et 
al., rehabilitation was superior to anti- TNFα therapy for improvements in anthropometric 
measures (44). Thus, physiotherapy and physical exercise may be a substantial supplement to 
medical treatment in order to improve mobility AS patients. Warm and stable climatic 
conditions may enhance rheumatic patients’ capacity to perform physical exercise (20), and 
this might explain why the improvements were larger when the rehabilitation was performed 
in a Mediterranean climate.  
The tests of physical capacity showed sustained, comparable improvements after 16 
weeks for both patient groups. The mean change in the 6-Minute Walk Test is judged to be of 
clinical significance when compared to studies of patients with respiratory diseases (45;46). 
The improvements in Timed Up and Go confirmed that the patients had improved their 
walking pace.  
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This study has some methodological limitations that have to be taken into 
consideration. More patients dropped out before the study started in the Norwegian group 
than in the Mediterranean group. This may have influenced the comparability of the two 
groups. We found some differences in baseline drugs, but the baseline values of all outcome 
measures were comparable.  
The climatic conditions were a main difference between the Mediterranean therapy 
and the Norwegian therapy given in this study, but we cannot ignore that the rehabilitation 
programmes had some differences even though the main components were similar. The 
Norwegian programme tended to focus more on endurance training and the Mediterranean 
programme more on mobility. Passive therapy including balneotherapy was given on a larger 
scale in the Mediterranean than in the Norwegian centres. Spa therapy has been shown to 
provide additional beneficial effect over standard treatment consisting of physical exercise 
and drug treatment alone for patients with ankylosing spondylitis (39;47;48). Thus, our 
conclusion about the differences in efficacy of rehabilitation in warm and cold climates must 
take into account more than the relationship between climatic conditions and AS. Further 
studies are needed to ascertain which are the most important contributing factors to these 
differences. 
In conclusion, this study shows that AS patients had a sustained positive effect of a 4-
week rehabilitation programme both in a Mediterranean and in a Norwegian climate. The 
improvements in the patient’s assessments of health status and spinal mobility measures were 
larger and better maintained at least 3 months after rehabilitation in a Mediterranean climate, 
while the improvements in physical capacity were comparable between the two groups. These 
results support the ASAS/EULAR recommendations of non pharmacological therapy 
(including education, exercise and physiotherapy) as an important part of the management of 
AS (5). 
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Table I   Baseline characteristics for AS patients receiving rehabilitation in a 
Mediterranean country or in Norway 
 
 Mediterranean 
group 
n=65 
Norwegian 
group 
n=42 
Demographic data    
 Female sex, n (%) 27 (42) 19 (45) 
 Age, years, mean (SD; range) 48 (10; 28 – 70) 51 (8; 30 - 62) 
 Married or living with a partner, n (%) 51 (79) 30 (71) 
 Years of education, mean (SD) 13 (3) 12 (3) 
 Employed full time/part time, n (%) 30 (46)/9 (14) 20 (48)/6 (14) 
 Once on sick leave during last 6 months, n (%) 17 (47) 14 (58) 
       
Disease characteristics     
 Disease duration, years, mean (SD) 17 (10) 18 (9) 
 HLA-B27 positive, n (%) 57 (88) 38 (93) 
 Co-morbidity      
 Hypertension, n (%) 12 (19) 13 (31) 
 Metabolic disorders, n (%) 8 (12) 2 (5) 
 Other diseases, n (%)* 7 (11) 6 (14) 
    
Baseline drugs (%)   
 NSAIDs or coxibs daily/when needed, n (%) 37 (58)/20 (31) 26 (62)/10 (24) 
 Analgesics daily/when needed, n (%) 6 (9)/42 (65) 4 (10)/19 (46) 
 DMARDs, n (%) 7 (11) 13 (33) § 
 Prednisolone, n (%) 4 (6) 9 (24) § 
 Daily prednisolone dose, mg, mean (SD) 5 (4) 5 
 Biological treatment, n (%) 1 (2) 3 (9) 
    
*Coronary artery disease n=3, renal diseases n=3, migraine n=3, asthma bronchiale n=2 and cancer n=2. 
§p<=0.01 versus patients treated in the Mediterranean group. 
NSAID, Non-steroid anti inflammatory drug; DMARD, disease-modifying antirheumatic drug. 
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Table III   Responses in spinal 
mobility, ESR and tests of physical 
capacity at 4 and 16 weeks after 
initiation of rehabilitation 
 
 
 
Baseline 
values 
Changes from baseline 
 
week 4 
 
p 
value 
 
week 16 
 
p 
value 
Spinal mobility 
 Anterior lumbar flexion 
(Schober), cm 
 
  Mediterranean group 3.3 (1.6) 0.7 (1.0) 0.001 0.5 (0.9) 0.001 
  Norwegian group 3.2 (1.5) 0.1 (0.5) 0.137 0.2 (0.5) 0.003 
  Difference between the groups   0.001  0.038 
 Lateral lumbar flexion, right, cm  
  Mediterranean group 8.6 (4.4) 4.9 (3.9) 0.001 4.5 (3.8) 0.001 
  Norwegian group 9.9 (5.7) 2.3 (3.5) 0.001 1.5 (2.8) 0.002 
  Difference between the groups   0.001  0.001 
 Lateral lumbar flexion, left, cm  
  Mediterranean group 8.3 (4.5) 5.1 (3.7) 0.001 4.7 (3.7) 0.001 
  Norwegian group 9.6 (5.4) 2.4 (3.3) 0.001 1.8 (3.1) 0.001 
  Difference between the groups   0.001  0.001 
 Chest expansion, cm      
  Mediterranean group 3.7 (1.6) 0.7 (1.4) 0.001 0.3 (1.5) 0.081 
  Norwegian group 3.9 (1.9) 0.2 (0.8) 0.174 0.3 (1.1) 0.142 
  Difference between the groups   0.023  0.792 
        
ESR, mm*      
  Mediterranean group 17.0 
(10.0,36.5) 
1.0 (11.0) 0.489 -8.3 (10.9) 0.001 
  Norwegian group 12.0 
(6.0,30.5) 
-3.5 (10.6) 0.039 -2.5 (10.6) 0.116 
  Difference between the groups   0.041  0.014 
        
Tests of physical capacity      
 6-Minute Walk Test (6MWT), m 
  Mediterranean group 559 (84) 84 (64) 0.001 68 (65) 0.001 
  Norwegian group 566 (99) 61 (53) 0.001 59 (54) 0.001 
  Difference between the groups   0.071  0.470 
 Timed Up and Go (TUG),speed (20m/second) 
  Mediterranean group 1.5 (0.3) 0.2 (0.2) 0.001 0.2 (0.2) 0.001 
  Norwegian group 1.5 (0.3) 0.2 (0.2) 0.001 0.1 (0.2) 0.027 
  Difference between the groups   0.069  0.116 
Baseline values are shown as mean (SD), and changes from baseline are shown as mean difference from 
baseline (SD), unless stated otherwise. *median (25th, 75th centile). Number of patients treated (n) was 65 in the 
Mediterranean group and 42 in the Norwegian group.   
ESR, erythrocyte sedimentation rate. 
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Figure Legends 
 
Figure 1. Summary of patient disposition, non-participants in italics, n=218 
(171+10+1+1+28+2+5). * The patients excluded from the analysis did not meet the Modified 
New York Criteria for Ankylosing Spondylitis (1984) at the first medical examination (35).  
 
Figure 2. Values above the bars are the percentages of the patients who met the Assessments in 
Ankylosing Spondylitis working group’s improvement criteria (ASAS-IC), ASAS20= 20% 
improvement and ASAS40= 40% improvement. The responses are measured at week 4, week16, 
and week 28 after initiation of treatment in the Mediterranean, n=65, or in the Norwegian climate, 
n=42. The differences between the groups are marked on the figure.  
 
Figure 3. Values above the bars are the percentages of the patients who had 20% and 40% 
improvement in A) anterior lumbar flexion (Schober) and B) lateral lumbar flexion on either the 
right or the left side. The responses are measured immediately after treatment (week 4) and 16 
weeks after initiation of treatment in the Mediterranean, n=65, or in the Norwegian climate, n=42. 
The differences between the groups are marked on the figure.  
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Figure 1   Patient flow  
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Analysed  (n= 65 ) 
 Excluded from analysis (did not meet the 
diagnostic criteria for Ankylosing Spondylitis*) 
(n= 1 ) 
Lost to follow-up at control after 3 months    
(n= 1 ) 
 
Allocated to intervention in Mediterranean 
climate (n= 77 ) 
 Received allocated intervention (n= 67 ) 
 Did not receive allocated intervention (chose 
not to participate after randomisation) (n= 10 ) 
Lost to follow-up at control after 3 months    
(n= 2 ) 
 
Allocated to intervention in Norway (n= 77 ) 
 Received allocated intervention (n= 49 ) 
 Did not receive allocated intervention (chose 
not to participate after randomisation) (n= 28 ) 
Analysed  (n= 42 ) 
 Excluded from analysis (did not meet the 
diagnostic criteria for Ankylosing Spondylitis*) 
(n= 5 ) 
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 Figure 2   ASAS improvement
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Figure 3A   Schober 20 and 40% improvement
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Figure 3B   Lateral flexion 20 and 40% improvement
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PATIENTS WITH NEUROMUSCULAR DISEASES BENEFIT FROM TREATMENT 
IN A WARM CLIMATE
Petra A. Nordby, PT1, Yndis A. Staalesen Strumse, MD2, Kathrine F. Frøslie, MSc3 and Johan 
K. Stanghelle, MD, PhD4
From the 1Sunnaas Rehabilitation Hospital, 2Department for Treatment Abroad, and 3Section of Biostatistics,  
Rikshospitalet-Radiumhospitalet Medical Centre and 4Sunnaas Rehabilitation Hospital and Faculty of Medicine  
University of Oslo, Oslo, Norway
Objective: Several studies have shown positive effects of 
treatment of chronic diseases in a warm climate. The aim of 
this study was to evaluate the long-term effect of a 4-week re-
habilitation programme in a warm climate for patients with 
neuromuscular diseases. 
Design: A randomized controlled trial with a cross-over de-
sign. One period of intervention and one period of “life as 
usual”.
Patients: A total of 60 persons with a neuromuscular diag-
nosis. 
Methods: Long-term effects were defined as changes in phys-
ical and psychological functions persisting after 3 months. 
Several scales were used according to the World Health Or-
ganization’s classification of functioning. 
Results: A comparison of the changes in the 2 periods showed 
significantly better results for all primary outcome scales in 
favour of the intervention. Mean difference in changes in 
pain (VAS scale), 6-min walking test and “timed up and go” 
were 9.0 (SD 28.8) units, 52 (75) m and 1.0 (2.3) sec, p = 0, 03, 
< 0.01 and 0.01, respectively. Median difference in changes 
in “Fatigue Severity Scale” and “Life Satisfaction Scale” 
were 0.4 (–0.5, 1.7) and 0.0 (0.0, 1.0), p = < 0.01 and 0.01, 
respectively.
Conclusion: This study shows positive long-term effects on 
different dimensions of health after a 4-week rehabilitation 
programme in a warm climate for patients with neuromus-
cular diseases. This effect might be due to the programme, 
the warm climate, or a combination of both.
Key words: neuromuscular disease, climate, rehabilitation, com-
parative study, treatment outcome.
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INTRODUCTION
The number of persons suffering from a neuromuscular disease 
in Norway is approximately 5000 (1–6). The heterogeneous 
group of neuromuscular diagnoses can be divided into 3 
main groups; myopathies, where the disease is located in the 
muscle ﬁbre or its energy metabolism, neuropathies (disease 
in the peripheral nerves), and neuromyopathies, where both 
the muscle ﬁbres and the nerves are affected (1–6). There 
are hereditary, congenital neuromuscular diseases in all of 
these 3 main groups. The diagnoses are relatively slowly 
progressive (2, 3, 6). Even though neuromuscular disorders 
are a heterogenic group, both in terms of pathophysiology 
and clinical manifestations, it is possible to identify common 
impairments that inﬂuence quality of life and ability to cope 
with everyday living. Some of the common problems and 
complaints are muscle weakness of various severity, exercise 
intolerance, reduced endurance, fatigue, pain and problems 
with ambulation (1, 7, 8).
Many individuals with neuromuscular diseases have reported 
that staying in countries with a warm climate for a period, or 
following a rehabilitation programme in countries with a warm 
climate, has positive effects on their health. The reported ef-
fects have been on both a physical and a psychosocial level, 
including health-related quality of life and general well- 
being. In Norway there is a long tradition of sending patients 
to warmer climates for intensive physiotherapy. This health 
service was originally offered to patients with rheumatic dis-
eases. A public report about this concept concludes that patients 
with other chronic, somatic diseases might also beneﬁt from 
treatment in a warm climate (9). 
Recommending treatment in a warm climate for various pa-
tient groups, especially persons with neuromuscular diseases, is 
controversial. Requests for such treatment from these patients 
themselves are increasing. This study was set up as a result of 
the claim that the effect of treatment in a warm climate should 
be evaluated thoroughly. The aim of this study was to evaluate 
whether treatment in a warmer climate had long-term effects 
on physical, psychological and social dimensions of health in 
persons with neuromuscular diseases. Long-term effects were 
deﬁned as changes in physical and psychological functions 
persisting 3 months after intervention.
METHODS
This study was announced in 6 of Norway’s largest daily newspapers 
and in the Norwegian neuromuscular organization’s newsletter. 
Information about the study was also sent to the local groups of 
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the Norwegian neuromuscular organization and to the 2 university 
hospitals in Norway with special units for neuromuscular diseases 
(Rikshospitalet-Radiumhospitalet Medical Centre and University 
Hospital of North Norway). 
The main inclusion criterion was a neuromuscular disease of heredi-
tary, slowly progressive type, diagnosed by a neurologist. In addition, 
participants should be able to handle primary activities of daily living 
without assistance (10). Participants were recruited from persons who 
answered the announcement and met the inclusion criteria.
Exclusion criteria were other medical conditions that could inﬂuence 
safe participation in the rehabilitation programme in a warm climate, 
such as serious cardiovascular disease, serious psychiatric conditions, 
and alcohol or drug addictions. 
Use of a manual or powered wheelchair did not exclude persons from 
the study, but due to airline company restrictions the inclusion of per-
sons with an absolute need for a powered wheelchair was limited. 
A total of 99 persons applied to participate in the study. Of these, 
67 met the inclusion criteria, and after a random draw 60 were invited 
to participate. 
 The study followed a cross-over design with 2 intervention periods 
(Fig. 1). The ﬁrst period started (ﬁrst baseline) in May 2003, with a 
4-week intervention in June for half of the participants, and a re-test in 
October (3 months after intervention) for all participants. The second 
period started in May 2004 with a baseline test (second baseline), and 
intervention was offered to the other half of the patients. Again, all 
participants were re-tested in October. Participants selected for inter-
vention in the ﬁrst or second period were determined by randomiza-
tion, after stratiﬁcation on diagnosis and use of powered wheelchair. 
Randomization was performed after the ﬁrst baseline examinations. 
The intervention was performed at Reuma-Sol centre, a modern 
rehabilitation centre situated on the coast of Spain (Costa Blanca), 
with facilities such as gym and swimming pools. The climate in Spain 
during the intervention periods was mostly dry and sunny, with mean 
temperatures of 25°C. The rehabilitation programme at Reuma-Sol was 
specially organized for the intervention periods (2003 and 2004) of this 
study. The participants received a combination of individual and group 
therapy with low to moderate intensities regarding both strength and 
endurance training. Depending on the weather and temperature, the 
indoor or outdoor pools were used for daily training, both in groups 
and for individual self-training activities. Furthermore, the programme 
included classes in relaxation, group training in the gym and instruc-
tion in self-training. The participants were a heterogeneous group 
and, in order to be able to provide an adapted level of training, the 
group was divided into 3 training groups based on clinical evaluation 
of physical function by the physiotherapists. In addition, each person 
was prescribed an individually adapted training programme based on 
his or her functional level.
The participants attended daily training/treatment in the swimming 
pool (60 min) and daily group training in the gym (60 min). Individual 
physiotherapy was received on average 4 times a week. The organi-
zation of the daily programme gave the participants opportunity to 
recover, do exercise or take a walk on their own, according to their 
individual need. A physician and a physical therapist from Sunnaas 
Rehabilitation Hospital were responsible for a patient education 
programme. 
The study period May to October includes the Norwegian summer. 
Norwegian climate during summer varies throughout the country. In 
northern Norway, the summer period is shorter and the temperature 
is lower than in the south, where the weather is more stable and dry. 
During this period in Norway the participants were told to “live as 
usual”, besides participating in the test procedures. Some of them had 
regular physiotherapy and/or pool training sessions or other physical 
activities, while others had no physical therapy or training. 
The outcome measures were chosen due to the complexity of a clinical 
evaluation of patients with neuromuscular diseases, which requires that 
a large variety of physical and psychological symptoms and complaints 
are taken into consideration. They also aimed to cover the 3 levels of the 
World Health Organization (WHO)’s deﬁned consequences of disease; 
body functions and structures, activities and participation (11). Based 
on the most common problems and previous ﬁndings during treatment 
in a warm climate for other patient groups, the following ﬁve primary 
outcome measures were chosen: for body functions and structures, pain 
registered on a visual analogue scale (VAS) (12) and Fatigue Sever-
ity Scale (13, 14); for activities, endurance (measured by a 6-minute 
walking test) (15, 16) and mobility/balance (measured by “timed up 
and go”) (17); and, for participation, Life Satisfaction Scale (18, 19). 
Secondary outcome measures were: Proﬁle of Mood States (POMS) 
(20), Health-related problems (measured by Holger Ursin Inventorium) 
(21), Rivermead Mobility Index (15), and fast walking (measured by a 
20-m walking test) (15, 16).
The participants were examined immediately before (week 0) and 3 
months after ending the 4-week rehabilitation period (week 16). Long-
term effects of intervention were deﬁned as changes in physical and 
psychological function persisting 3 months after intervention. 
Several of the outcome measure scales used in this study are based 
on numerical scales, and some are based on ordinal scales. Descriptive 
statistics for the ordinal scales are presented as median and quartiles, and 
the corresponding tests are non-parametric; Mann-Whitney U-test for 
unpaired data and Wilcoxon signed-rank test for paired data. Descriptive 
Fig. 1. Study design and ﬂow of participants through each stage of the 
trial. 
Assessment of all participants three months after
intervention (n=58¹)
¹ Four persons answered the questionnaires but did not attend
physical testing.
Group B:
-Four weeks rehabilitation in Spain
(n=25)
- Withdrew before start: due to delivery
(n=1), poor health condition (n=1),
responsibilities at home (n=1), planned
vacation (n=1), anxiety of insufficient
assistence (n=1)
-Completed intervention (n=25)
Assessment of all participants three months after
intervention (n=53¹)
¹ Four persons answered the questionnaires but did not attend
physical testing.
Group A:
- Daily life in Norway, without
intervention (n=28)
- Completed the period (n=28)
1 drop-out due to personal problems
(n=28)
Allocated in Group B:
-Daily life in Norway without
intervention (n=30)
- Completed the period (n=30)
Allocated in Group A:
- 4 weeks rehabilitation in Spain
(n=30)
- Withdrew due to family problems
(n=1)
-Completed intervention (n=29)        
Completed baseline assessment at Sunnaas
Rehabilitation Hospital (questionnaires and physical
tests)
(n=60)
Stratified randomization into one of two groups.
Group A, first period in Spain, Group B, first period
in Norway.
60 participants (n=60) was included and consented
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statistics for the numerical scales are presented as mean and standard de-
viation (SD), and the corresponding tests are parametric tests; 2-sample 
and paired t-tests for unpaired data and paired data, respectively.
The data from the cross-over study were analysed as described 
elsewhere (22: p. 467–471). No signiﬁcant period or carry-over effects 
were found for the changes, and the analyses were therefore performed 
on the material as a whole, not regarding the order in which intervention 
was given. Paired t-tests and Wilcoxon test for paired samples were 
used to analyse the changes from baseline (May) to re-test (October), 
both for the intervention period and for the control period. 
Paired t-tests and Wilcoxon test for paired samples were also used 
to compare the changes in the intervention period with the changes in 
the control period. The numbers reported in the results (p-values and 
conﬁdence intervals (CI)) were not adjusted for multiple testing, as all 
tests represent comparisons of only 2 different settings (intervention 
and “life as usual”). However, the choice of 5 different primary meas-
ures still raises the question of adjustment due to multiple testing, and 
a Bonferroni-type approach was considered, with a correction factor of 
5. Two-sample t-tests and Mann-Whitney U-tests were used to analyse 
gender differences. No other stratiﬁed analyses were performed. The 
computer program SPSS 12.0 was used for all analyses. A p-value less 
than 0.05 was considered statistically signiﬁcant.
Ethics
The study was approved by the internal ethics committee at the Sunnaas 
Rehabilitation Hospital, University of Oslo, based on the fact that an al-
most identical study on patients with post-polio syndrome was approved 
by the Regional Ethics Committee of Eastern Norway the year before 
(23). All participants gave their written consent, and could withdraw 
from the study at any time without giving a speciﬁc reason.
RESULTS
The study design, number of participants and drop-outs are 
shown in Fig. 1. There were some missing values because 
some participants only answered postal questionnaires and 
did not meet for physical testing. Due to drop-out and missing 
physical tests, the total numbers of measurements used in the 
analyses varied between 42 and 53. All participants followed 
the prescribed programme with only minor deviations, based 
on therapists’ statements.
Demographic factors and disease related factors, including 
diagnoses, are summarized in Table Ι. More women than men 
(38 vs 22) participated in the study. This does not reﬂect the 
gender distribution in the patient population. Although the 
participants were able to handle primary activities of daily 
living (ADL) without assistance, the median score on Sunnaas 
ADL Index (0–36) was 32.5. This indicates that the group had 
a considerable reduction in functional ability. Most of the 
participants were in need of orthopaedic devices and techni-
cal aids, and 20 persons had other diseases not related to their 
primary diagnosis. These were diseases that did not interfere 
substantially with the training, such as mild hypertension, al-
lergy, asthma, diabetes mellitus and hyper/hypo-thyroidism. 
Hereditary motor and sensory neuropathy (HMSN) was the 
most frequent diagnosis among the participants (n = 23), 
twice as often as limb-girdle muscular dystrophy (n = 10) and 
myotonic dystrophy (n = 11). A small group of the participants 
were diagnosed with spinal muscular atrophy (n = 3). 
Baseline data from the ﬁrst test, before randomization, are 
shown in Table ΙΙ. This table also gives descriptive statistics for 
changes in all outcome measures related to both intervention 
in Spain, and to a stay in Norway during summer. The effects 
of intervention, expressed as changes from baseline (week 0) 
to re-test 3 months after 1 month of intervention (week 16), 
showed improvement in all outcome measures, except for the 
Table Ι. Patient characteristics. Mean and standard deviation (SD) are given for age, age at diagnosis and body mass index (BMI). Median and 
quartiles are given for activities of daily living (ADL) score
Patient characteristics
Persons randomized to participate in a 
rehabilitation programme in Spain during 
the ﬁrst period and to “life as usual” in 
Norway during the second period
Persons randomized to “life as usual” 
in Norway during the ﬁrst period and to 
participate in a rehabilitation programme 
in Spain during the second period All
Participants (n) 30 30 60
Gender, female/male (n) 15/15 23/7 38/22
Age, years 42.5 (10.9) 46.0 (12.4) 44.3 (11.7)
Age at diagnosis, years 26.0 (16.6) 28.0 (14.5) 27.0 (15.4)
Married/ cohabitant (n) 16 22 38
Above basic education (n) 26 27 53
Full or part-time employment (n) 11 9 20
ADL-score, Sunnaas ADL index 33.5 (29.7, 36.0) 32 (27.7, 36.0) 32.5 (29.0, 36.0)
Wheelchair, manual (n) 5 7 12
Wheelchair, powered (n) 7 11 18
BMI* 24.0 (3.6) 26.0 (5,5) 25.0 (4.8)
Other diseases (n) 6 14 20
On prescribed medication (n) 8 16 24
Diagnoses
Hereditary motor and sensory neuropathy, 
HMSN (n)
11 12 23
Limb-girdle muscular dystrophy (n) 5 5 10
Myotonic dystrophy (n) 6 5 11
Spinal muscular atrophy (n) 2 1 3
Other (n) 6 7 13
*BMI: weight / height².
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status quo found in the Rivermead Mobility Index and life 
satisfaction. In contrast, long-term effects of being in Norway 
during the summer, expressed as changes in outcome measures 
from week 0 to week 16, showed mostly non-signiﬁcant, but 
slightly negative, results. Life satisfaction represented the only 
signiﬁcant outcome measure, with a negative change from 
week 0 to week 16. 
Table ΙΙ also shows differences between intervention and 
“life as usual” in Norway, expressed as changes from week 0 
to week 16 in the 2 periods. The changes, summarized in means 
and medians are in favour of the intervention in warm climate 
for all outcome measures, except for the Rivermead Mobility 
Index, which did not show any signiﬁcant change. No gender 
differences were found (data not shown).
All p-values and conﬁdence intervals given in Table ΙΙ are 
reported without adjustment for multiple testing. However, all 
signiﬁcant p-values found in the primary measures in Table ΙΙ, 
except for the overall difference in pain, would still have been 
signiﬁcant if adjusted by a factor of 5. 
DISCUSSION
This study shows positive long-term effects on physical 
function, health-related quality of life and general well- 
being following a 4-week rehabilitation programme in a 
warm climate for persons with neuromuscular diseases. Sta-
tistically signiﬁcant improvements were found in the primary 
outcome measure for pain (VAS), endurance (6-min walking 
test (6MWT)), fatigue (Fatigue Severity Scale) and mobility 
(timed “up and go”) after a 4-week rehabilitation programme 
in a warm climate. Whether these improvements are clinically 
signiﬁcant is debatable. In a study on acute pain in emergency 
medicine (24), the minimal clinically signiﬁcant difference 
(MCSD) in VAS pain score is determined to be 12 mm (95% 
CI: 9–15 mm). This study concludes that the MCSD in VAS 
pain score does not differ with the severity of pain experienced. 
Another study of patients with both traumatic and non-trau-
matic pain found the MCSD in VAS pain score to be 9 mm (95% 
CI 6–13 mm), and that the MCSD did not differ signiﬁcant 
according to age, sex and cause of pain (25). Hence, our ﬁnd-
ing of a 9.0 mm (95% CI 0.9–17.1) mean difference between 
intervention (Spain) and Norway in change from baseline might 
be considered borderline clinically signiﬁcant.
In the present study the mean baseline of the 6MWT was 
387 m, and the mean difference for the intervention group was 
54 m, which represents a 14% improvement. Other studies 
with 6MWT as the primary outcome measure differ in their 
deﬁnition of MCSD, from 30 and 56 m (26, 27). Enright (28) 
reports that a 12–40% mean improvement from baseline values 
has been published for various interventions. 
In fact, some improvements attained in this study are on 
the border of clinical signiﬁcance. Bearing in mind that these 
patients have neuromuscular diseases of a slowly progressive 
nature, this could be an interesting ﬁnding. If the improvements 
were artiﬁcially better results due only to the positive attention 
of being included in a study; the so-called Hawthorne effect 
(29), one should expect the same effect for both the Norway 
and Spain period. 
Table ΙΙ. Outcome measures from the first baseline, before randomization. Summary of changes in outcome measures related to intervention in 
Spain (I) and to “life as usual” Norway (N). Differences between intervention in warm climate vs “life as usual” in Norway
Outcome measures
First baseline, before 
randomization
Changes from baseline (week 0) 
to re-test (week 16)
Difference in changes from week 0 to 
week 16 between I and N
n
Mean (SD) 
*Median (Q1, Q3) Min–Max 
Mean (SD) 
*Median (Q1,Q3) p
Mean (SD) 
*Median (Q1, Q3) 95% CI p
Primary outcome measures
Pain (VAS) (0–100 mm) 51 24.5 (25.1) 0–92 I: 9.2 (21.9)N: 0.2 (15.1)
< 0.01
0.90 9.0 (28.8) [0.9, 17.1] 0.03
Fatigue (Fatigue Severity Scale) 
(1–7)* 53
4.7 (4.0– 5.5) 1.8–6.8 I: 0.5 (–0.2, 1.6)
N: –0.1 (–0.7, 0.4)
< 0.001
0.14 0.4 (–0.5, 1.7) < 0.01
Life Satisfaction (Life Sat. Scale) 
(1–6)* 53
5.0 (4.0, 5.0) 3.0–6.0 I: 0.0 (0.0, 1.0)
N: 0.0 (–1.0, 0.0)
0.23
< 0.01 0.0 (0.0, 1.0) 0.01
Walking endurance (6-min 
walking test) (m) 44
387 (85) 175–556 I: 54 (65)
N: 2 (38)
< 0.001
0.62 52 (75) [29, 75] < 0.01
Mobility/balance (timed “up and 
go”) (sec) 42
8.8 (5.1) 4.0–38.0 I: 1.0 (1.4)
N: 0.0 (1.5)
< 0.001
1.0 1.0 (2.3) [0.3, 1.8] 0.01
Secondary outcome measures
Feeling, affect and mood (POMS 
totalscore)* 47
126 (105, 141) 81–189 I: 13 (1, 24)
N: –3 (–22, 11)
< 0.001
0.23 13 (–7, 39) < 0.01
Health-related problems (Ursin 
Invent.) (0–90)* 52
9.0 (6.3, 18.0) 0.0–29.0 I: 2.0 (–1.0, 6.0)
N: –1.0 (–7.0, 2.0)
0.01
0.07 4.0 (–1.8, 10.0) < 0.01
Mobility (Rivermead Mobility 
Index) (0–15)* 53
14.0 (11.0, 15.0) 5.0–15.0 I: 0.0 (0.0, 0.0)
N: 0.0 (–0.5, 0.0)
0.93
0.11 0.0 (–0.5, 1.0) 0.40
Walking speed (20 m walking) 
(sec) 43
17.3 (10.7) 9.0–78.0 I: 1.8 (3.9)
N: –0.7 (3.3)
< 0.01
0.13 2.6 (6.7) [0.5, 4.7] 0.02
*Indicating outcome measures based on ordinal scales, analysed with non-parametric statistics. Descriptive statistics are presented as medians and 
quartiles.
SD: Standard Deviation; VAS: Visual Analogue Scale; POMS: Proﬁle of Mood States.
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Why should patients with neuromuscular diseases proﬁt from 
treatment in a warm climate? It has been shown previously that 
persons with neuromuscular disorders may proﬁt from regular 
physical training and treatment (30–33). However, when the 
physical training is carried out in a warm climate, a number of 
other factors are introduced that might also inﬂuence the result. 
Not only the higher temperature, but the contact with other 
people with the same problems, the change of environment, 
being far away from home and daily duties such as work and 
housework, and less limitations of physical activity might be of 
importance. This study did not control for these factors, thus one 
has to look upon the intervention as multifactorial. Two similar 
studies of training in a warm climate have shown a better effect 
of physiotherapy in a warm climate than in a cold climate for 
patients with neuromuscular diseases (34) and post-polio syn-
drome (23), respectively; although neither study was controlled 
for the additional factors related to a warm climate.
When isolating the different aspects of treatment in a warm 
climate is difﬁcult, the interpretation of the mechanism of ef-
fect becomes complicated. The patients report that it is not only 
the structured training programme or the warm climate that is 
important, but the combination of these. Having time to recover 
after training/treatment was also thought to be important. Fi-
nally, the patients found it beneﬁcial that the rehabilitation was 
provided for a group of patients with similar diagnosis. Many of 
the participants experience social isolation at home due to their 
physical limitations. To meet other people with the same types 
of diagnoses can be valuable in terms of handling the stress that 
may derive from loss of abilities regarded as valuable (35).
The questionnaire Life Satisfaction Scale did not show 
signiﬁcantly improved quality of life 3 months after a 4-week 
rehabilitation period in Spain. This is in contrast to the impres-
sion based on the participants’ statements. A possible explana-
tion may be that this questionnaire focuses on satisfaction with 
life in general and everyday life, and might not be sensitive to 
possible changes in aspects such as coping and self-esteem.
Many of the participants in the present study regularly fol-
lowed physical training and treatment at home 1–2 times a 
week. Weekly training and treatment with a frequency of 1–2 
times per week might have more effect on preserving functional 
level/maintaining function, while a continuous, co-ordinated 
training programme at an adapted level appears to be more 
useful for improving physical function. 
In this study, long-term effect was deﬁned as 3 months; after 
this no further follow-up was performed. Eleven months after 
intervention (second baseline) the gained effect was returned 
to the ﬁrst baseline level. The fact that no carry-over effect was 
found is methodologically important when using cross-over 
design, and this indicates that the effect of the intervention 
vanishes before 11 months. Dahl et al. (34) reported an effect on 
the 6-min walking test 6 months after intervention for patients 
with neuromuscular disease. Strumse et al. (23) showed that 
effect on most outcomes persists 6 months after intervention 
in patients with post-polio syndrome.
When it comes to methodological considerations, there are 
some potential biases in our study: the fact that the participants 
self-selected into this study implicates a selected part of the 
total patient population. More women than men (38 vs 22) 
participated in the study, and since this does not reﬂect the 
gender distribution in this patient population, it might be a 
bias. Differences in the composition of the 2 groups comprise 
fewer problems in cross-over designs: all participants undergo 
the same intervention and it is the comparison between Norway 
and Spain that is interesting.
This study includes persons with different neuromuscular 
diseases. Ideally, one should study each diagnosis in isolation, 
but since each neuromuscular disease has a low prevalence, it 
is difﬁcult to ﬁnd enough patients for this purpose. However, 
as this study focuses on changes at the functional level, which 
is a common subject for these patients, it might be acceptable 
to merge different conditions. 
A co-ordinated rehabilitation programme in a warm climate 
is considered a valuable complement to the existing programme 
for these patients. It is important that the basic medical and 
training services in national rehabilitation centres are avail-
able for all, and especially for those with contraindications 
to travelling abroad. Treatment in a warmer climate could 
be included in an individual rehabilitation plan, based on a 
recommendation from a specialist.
In conclusion, this study shows positive effects on different 
dimensions of health of at least 3 months’ duration following a 
4-week rehabilitation programme in a warm climate for patients 
with neuromuscular diseases. However, the study does not show 
what part of the programme is the most effective. Treatment in 
a warm climate comprised 2 main aspects; intensive physical 
training/treatment and warm climate, but there were also a va-
riety of confounding variables, such as being away from home, 
social contact, and being free from everyday duties, allowing 
the possibility of recovery after training. There is a need for 
future studies with a complementary design, such as a control 
group following an organized training/treatment programme in 
Norway and a group in a warm climate without intervention. 
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